WVSHP Logo Contact Information
News & Events

News from WVSHP

WVSHP Annual Residency Showcase Updated 10/10/2018: Driving directions, parking Information, and Showcase Residency Programs list now available. SAVE THE DATE WVSHP Annual Residency Showcase Saturday October 20th, 2018 Being Held at the WVU School of Pharmacy Registration coming soon. (Click for more...) 2019 Spring Meeting - Save the date SAVE THE DATE for the Spring Meeting 2019 April 26th and 27th, 2019 Embassy Suites, Charleston, WV (Click for more...) ASHP and ACPE revised guidelines ASHP and the Accreditation Council for Pharmacy Education (ACPE) just released revisions to the Accreditation Standards for Pharmacy Technician Educat (Click for more...)

News from elsewhere...
Merck KGaA announces new results for bifunctional immunotherapy M7824 10/22/2018 11:24:19 AM Includes data for head and neck cancer, biliary tract cancer and esophageal cancers (Click for more...) Sanofi's Dupixent set for $2.5B in peak asthma sales after scoring winning label: analyst 10/22/2018 11:21:58 AM Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost, according to an analyst. (Click for more...) Strong results for Keytruda in head and neck cancer 10/22/2018 11:18:06 AM MSD's immunotherapy improved overall survival by up to 39% (Click for more...) Mandatory PDMP checks may not be beneficial for surgical patients 10/22/2018 11:09:32 AM Mandatory PDMP checks may not be beneficial for surgical patients Mon, 10/22/2018 - 11:16 caldridgeyoung… Mon, 10/22/2018 - 11:09 New data published in JAMA Surgery show that mandating surgeons perform a P (Click for more...) Experts Gather for a Pair of Pharma & Biotech Conferences 10/22/2018 11:07:38 AM From October 29-30, London will be the site of two important events for the pharma and biotech industries, the 2nd Medicinal Chemistry Summit: Europe and the 2nd Global Pharma R&D Informatics & AI Congress. Presented by Global Engage, the conferences will be co-located at the Radisson Blu Edwardian Heathrow, opening up the opportunity for industry […] (Click for more...) Bristol-Myers' Opdivo-Yervoy combo hits a regulatory snag in lung cancer 10/22/2018 10:54:12 AM Bristol-Myers Squibb presented a raft of results for its Opdivo-Yervoy immuno-oncology combo across multiple tumor types at the European Society for Medical Oncology meeting. But results it didn’t present stole the weekend spotlight. (Click for more...) Merck KGaA opens $72M distribution facility at German headquarters 10/22/2018 10:51:34 AM Merck KGaA has opened a new distribution center as it continues to streamline its manufacturing and build up the production site at its headquarters in Darmstadt, Germany. (Click for more...) ESMO18: Merck's Keytruda, alone and in combo, makes its case for earlier use in head and neck cancer 10/22/2018 10:03:30 AM After batting aside efficacy questions in head and neck cancer, Merck’s Keytruda is back with a new batch of positive data, this time in previously untreated patients. (Click for more...) Recipharm reverses decision to close plant in Sweden, but faces action on another facility in U.K. 10/22/2018 9:43:04 AM Recipharm faced a classic good news-bad news situation last week. The good news is that a plant slated to close will remain open. The bad news is that U.K. authorities cited a different facility over the potential for cross contamination of products. (Click for more...) Pharma CEOs lean Republican with 2018 election donations. So who's the sole Democrat? 10/22/2018 9:18:15 AM Big Pharma CEOs at Merck, Pfizer, Eli Lilly and more gave mostly to Republicans this election season. But one CEO went full blue with his donations, giving $120,000 to Democratic causes, MarketWatch reports. (Click for more...) ESMO18: Bristol-Myers Squibb eyes lead in rare colorectal cancer with new Opdivo results 10/22/2018 6:57:23 AM Bristol-Myers Squibb is looking to push its Opdivo-Yervoy combo further into colorectal cancer, and with new phase 2 data in previously untreated patients, it just might be able to. (Click for more...) AZ and MSD’s Lynparza shows significant results in ovarian cancer 10/22/2018 6:12:36 AM Drug improved progression-free survival by 70% (Click for more...) Two trial wins for Roche’s immunotherapy Tecentriq 10/22/2018 5:47:57 AM Positive results in lung and breast cancer, but Roche is still playing catch-up to rival drugs (Click for more...) Medicines Discovery Catapult and AstraZeneca collaborate for acoustic mist ionisation mass spectrometry 10/22/2018 5:07:54 AM AMI-MS delivers a twenty-fold improvement in throughput compared to traditional mass spectrometry by using sound energy (Click for more...) ESMO: Roche's latest Tecentriq lung results underscore Avastin's talents, executive says 10/22/2018 3:12:30 AM New data presented on Monday show that Roche’s Tecentriq, in tandem with chemo, can help newly diagnosed lung cancer patients live longer. But what they didn’t show may be just as important, one executive figures, particularly for the company's bid to expand Avastin along with Tecentriq. (Click for more...) What's next for pharma in the advancing battle over drug prices in TV ads? 10/21/2018 11:46:15 PM Last week, the Trump administration put it in writing: Under a proposal published in the Federal Register, drugmakers will have to put list prices in their TV ads. So what's next for pharma? Here's what our experts say. (Click for more...) Bupivacaine with Epinephrine Injection 10/21/2018 8:00:00 PM Drug: Bupivacaine with Epinephrine Injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) Hydralazine injection 10/21/2018 8:00:00 PM Drug: Hydralazine injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) Lidocaine with Epinephrine Injection 10/21/2018 8:00:00 PM Drug: Lidocaine with Epinephrine Injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) Magnesium Sulfate Injection 10/21/2018 8:00:00 PM Drug: Magnesium Sulfate Injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) Mepivacaine Injection 10/21/2018 8:00:00 PM Drug: Mepivacaine Injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) Sodium Phosphate Injection 10/21/2018 8:00:00 PM Drug: Sodium Phosphate Injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) Vancomycin Hydrochloride Injection 10/21/2018 8:00:00 PM Drug: Vancomycin Hydrochloride Injection, Revision Date: Mon, 22 Oct 2018 (Click for more...) ESMO18: Mammoth Lynparza survival win puts AstraZeneca, Merck in line for $1B launch 10/21/2018 6:13:57 AM AstraZeneca and Merck’s Lynparza is the first in its ultracompetitive class of PARP inhibitors to post positive data in BRCA-mutated ovarian cancer patients who've just wrapped up an initial round of chemo. And it’s entering with a bang. (Click for more...) ESMO18: Pfizer preps for Bristol-Myers Squibb showdown with Bavencio kidney cancer combination data 10/21/2018 4:33:27 AM Pfizer has long been a player in kidney cancer, but it’s looking to take things up a notch—and challenge next-generation rival Bristol-Myers Squibb—with its latest data. (Click for more...) ESMO: Roche's Tecentriq posts 'unprecedented' benefit in triple-negative breast cancer 10/20/2018 9:02:18 AM Roche’s Tecentriq is gunning to become first in its class of immuno-oncology agents to score an indication in tough-to-treat triple-negative breast cancer, and it’s out with the data that could help it get the job done. (Click for more...) ESMO: Pfizer's narrow Ibrance survival miss could still sway doctors in its favor, executives say 10/20/2018 8:17:54 AM Pfizer’s Ibrance may have failed to show it could help some breast cancer patients live longer. But executives say digging into those study results—from the closely watched Paloma-3 trial—still reveals a “compelling” case. (Click for more...) More older adults plan to use online pharmacies, other tech for aging in place 10/19/2018 10:05:01 PM More older adults plan to use online pharmacies, other tech for aging in place Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Retirees would rather age in their homes by utilizing technology rather than move into an assisted living facility, according to a study by Retirement Living. The study, which questioned more than 2,300 adults aged 50 years and older, found that 80% of respondents said they plan to age in place, with almost 52% stating that they would hire a caregiver if they could no longer care for themselves. Although many respondents said they are still unsure about how they will use technology as they age, more than one-half reported they are "likely or very likely" to use online pharmacies. About 40% of respondents reported they would use medical alert systems and food delivery services. Meanwhile, 75% of respondents said they planned to make some modifications to their bathrooms, like installing grab bars, to prevent them from moving to an assisted care facility. (Click for more...) FDA proposes critical first steps to harmonize global scientific and technical standards for generic drugs 10/19/2018 10:05:01 PM FDA proposes critical first steps to harmonize global scientific and technical standards for generic drugs Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 FDA has proposed the pursuit of common global development standards for generic drugs to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. FDA Commissioner Scott Gottlieb says a single global drug development program would make it easier for developers that would otherwise only seek generic drug approval in one region to also seek approval in the United States. "And it would also make it easier for developers that would otherwise only seek generic drug approval in the U.S. market to gain access to other markets," says Gottlieb. The ultimate goal of this global harmonization of scientific and technical requirements would be the attainment of a single global generic drug development program that can support simultaneous regulatory filings across multiple markets. Currently, manufacturing specifications may differ between countries, and different types of tests may be required to support the approval of a generic drug in different countries. "The lack of harmonization across such basic components of generic drug development reduces the opportunities for generic drug developers to use their data and information across multiple applications in different jurisdictions," notes Gottlieb. "The result is increased cost and complexity to the generic drug development and approval process, which makes it more difficult for generic drug developers to file applications for approval in different markets for a generic drug." (Click for more...) HHS activates aid for uninsured Floridians needing medicine after Hurricane Michael 10/19/2018 10:05:01 PM HHS activates aid for uninsured Floridians needing medicine after Hurricane Michael Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 In the aftermath of Hurricane Michael, HHS reports that thousands of Florida residents with no health insurance are eligible for free replacements of key medications that were lost or damaged in the storm. The Emergency Prescription Assistance Program (EPAP), managed by HHS' Office of the Assistant Secretary for Preparedness and Response, covers prescriptions for uninsured individuals who are affected by disasters. In Florida, more than 4,900 pharmacies participate in the program. "The Emergency Prescription Assistance Program provides vital assistance to people without insurance who rely upon certain prescription medicines to protect their health after disasters," said HHS' Assistant Secretary for Preparedness and Response Robert Kadlec, MD. "I encourage citizens in Florida who can use this assistance to take advantage of it to ensure they have an adequate supply of the medicines they need." Under EPAP, uninsured patients needing certain medicines during an emergency can obtain a 30-day supply at any participating pharmacy through November 15. In addition, those without insurance may also be able to use the program to replace some medical supplies, vaccines, or medical equipment that were damaged or lost as a direct result of the hurricane, or as a secondary result of loss or damage that occurred while in transit from the emergency site to an emergency shelter. (Click for more...) Massachusetts expands access to opioid reversal medication 10/19/2018 10:05:01 PM Massachusetts expands access to opioid reversal medication Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Gov. Charlie Baker of Massachusetts said Thursday the state Department of Health has issued a standing order for the distribution of naloxone. The order, mandated under a broader opioids bill the governor signed earlier this year, enables pharmacies across the state to dispense naloxone without a prescription. Additionally, Baker said Massachusetts will use $36 million in federal funding to provide addiction treatment medications to more inmates at county jails, among other programs. (Click for more...) Opioid makers ask counties for proof of harm 10/19/2018 10:05:01 PM Opioid makers ask counties for proof of harm Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Purdue Pharma has asked counties suing the drug manufacturer for allegedly causing the opioid epidemic to offer specific details to back up their claims. The counties suing opioid makers say pointing to exact overdose deaths or excessive prescriptions is not necessary to prove their case that the drugmakers created an oversupply of opioids that resulted in a costly public health crisis. On Tuesday, U.S. District Judge Dan Polster in Cleveland ordered four Ohio cities and counties to identify 500 medically unnecessary prescriptions and 300 residents who became addicted or were harmed from opioid prescriptions. He said the plaintiffs do not have to produce those details if they promise not to argue in court that specific prescriptions were to blame for alleged deaths and other harms. Instead, he said, they will have to rely solely on broad arguments that look at the entire scope of the opioid crisis in their regions. More than 30 states and hundreds of local governments are pressing claims against drugmakers including Purdue, Endo International, Johnson & Johnson and Allergan, alleging their misleading marketing played down the addictive risks of opioids and helped fuel the drug epidemic. Many of the municipalities are also suing drug distributors and pharmacies, saying they didn’t do enough to stop suspicious orders flooding into their communities. (Click for more...) Effects of n-3 fatty acid supplements in diabetes mellitus 10/19/2018 10:05:01 PM Effects of n-3 fatty acid supplements in diabetes mellitus Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 As part of the ASCEND clinical trial, researchers compared cardiovascular outcomes over a mean 7.4 years in diabetic patients randomized to take or not take n-3 fatty acids. None of the 15,480 participants were known to have preexisting atherosclerotic cardiovascular disease. The primary endpoint, the first serious vascular event, occurred in 8.9% of patients randomized to a daily regimen of n-3 fatty acids, also known as omega-3. Similarly, the rate of nonfatal myocardial infarction or stroke, transient ischemic attack, or vascular death was 9.2% in patients who received a matching placebo consisting of olive oil. There also was no meaningful between-group difference in terms of composite outcome of a serious vascular event or revascularization; any-cause mortality; or rate of nonfatal serious adverse events. Based on the evidence, the investigators conclude that daily omega-3 intake does not reduce the risk of serious vascular events in individuals who have diabetes but not cardiovascular disease. (Click for more...) Effects of aspirin for primary prevention in persons with diabetes mellitus 10/19/2018 10:05:01 PM Effects of aspirin for primary prevention in persons with diabetes mellitus Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Addressing the cardiovascular (CV) risks linked to diabetes while avoiding additional harms continues to be a balancing act, according to researchers involved in the ASCEND clinical study, who point to the dilemma with aspirin therapy. Working with a sample population of 15,480 adults with diabetes but no CV disease, the investigators randomly allocated trial participants to a daily dose of 100 mg of aspirin or matching placebo, with a mean followup period of 7.4 years. At that point, the risk of myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause—the primary efficacy outcome—was 12% lower for the aspirin group compared with the controls. At the same time, the risk of major bleeding events—the primary safety endpoint—was 29% higher for aspirin takers vs. placebo takers. The bleeding dangers largely offset the absolute benefits of aspirin therapy in the setting of diabetes with no CV disease. (Click for more...) FDA panel delivers mixed views for two new opioids 10/19/2018 10:05:01 PM FDA panel delivers mixed views for two new opioids Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Two new opioid drug candidates went before an FDA committee last week, with one getting a nod from the panel and the other falling just shy of approval. The Anesthetic and Analgesic Drug Products Advisory Committee declined to recommend oliceridine, an opioid injection for management of moderate to severe acute pain in adult patients. The first in a new class of mcg-opioid receptor ligands that selectively activate the G-protein pathway, which is associated with pain relief, the novel agent aims to provide analgesia just as fast as morphine but with accelerated onset, reduced respiratory depression, less sedation, and fewer gastrointestinal effects. However, committee chair Raeford Brown Jr., MD, of the University of Kentucky, Lexington, said that study results were disappointing. "The problem with this drug is that it's not a substantial improvement over what we have now," he said. While committee members voted down oliceridine, they did favor a sufentanil tablet designed for rapid pain relief. The synthetic opioid, which is as much as 10 times more potent than fentanyl, is already available for I.V. and epidural anesthesia and analgesia under the care of an anesthesia provider; but the new sublingual preparation was envisioned as an option for people who cannot swallow oral medications and/or lack access to I.V. opioids. If approved, it will be the first sufentanil analgesic for sublingual use—although it still will be not be available in the home or community pharmacy settings. Despite winning over the committee, the drug is not without its critics—including Brown, who argues that sufentanil should be reserved for use in the operating room, "where there are airway management experts available." (Click for more...) International 'safe abortions' service can now ship to women in U.S. 10/19/2018 10:05:01 PM International 'safe abortions' service can now ship to women in U.S. Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Women on Web, a group that has long provided medication to help women induce abortions at home in countries where abortion is outlawed is now shipping to the United States. The group operates an online service to ship misoprostol and mifepristone tablets to pregnant people worldwide. Taken together, the two medications are about 97% effective in inducing abortion within the first trimester. Women on Web's founder Rebecca Gomperts is starting a new service, called Aid Access, to ship to U.S. women. The service will screen women to determine whether they can take the tablets. Gomperts, a Dutch physician, will fill the prescriptions herself and send them through an Indian pharmacy directly to customers' homes in the United States. Anti-abortion activists have argued that the tablets are not safe, though doctors have said otherwise. The World Health Organization also recognizes the type of service Gomperts provides as a safe and effective option for women. (Click for more...) CVS Pharmacy completes statewide rollout of time delay safes in Ohio stores 10/19/2018 10:05:01 PM CVS Pharmacy completes statewide rollout of time delay safes in Ohio stores Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 CVS Pharmacy is now using time delay safes in all of its more than 300 Ohio locations. The safes are used to help prevent pharmacy robberies as well as fight the opioid crisis by keeping opioids out of the hands of unauthorized individuals. "The installation of time delay safes at pharmacies in several of our Ohio markets has proven to be a deterrent for pharmacy robbers," said Alisa Ulrey, division vice president of CVS Pharmacy in Ohio. "We know that time delay safes, combined with other security policies and procedures in place at our stores, have drastically reduced robberies in our pharmacies and we are pleased to be able to implement them in all of our Ohio stores." (Click for more...) Express Scripts offers new value-based program for migraine 10/19/2018 10:05:01 PM Express Scripts offers new value-based program for migraine Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 Express Scripts says its new SafeGuardRx Migraine Care Value program will begin on April 1, 2019. Harold Carter, PharmD, senior director, Product, Express Scripts says: "Through the clinical care provided through our new Migraine Care Value program, Express Scripts specialist pharmacists in our Neuroscience Therapeutic Resource Center will identify patients using high amounts of acute migraine treatments, and work with them and their physician to move them to an appropriate preventive treatment." Once on preventive therapy, neuroscience specialist pharmacists will offer coaching for members to achieve optimal medication adherence and avoid migraine triggers. For members using newer calcitonin gene-related peptide (CGRP) inhibitors, pharmacists will offer coaching on using these injectable medications and overcoming barriers to achieving optimal results. CRGP inhibitors are costlier than previously available preventive migraine therapies, so they require conscientious management to ensure optimal patient outcomes. For patients who meet the clinical guidelines for CGRP therapy, the Migraine Care Value program will prefer erenumab-aooe (Aimovig—Amgen) and galcanezumab-gnlm (Emgality—Eli Lilly). (Click for more...) Trump wants drug commercials to include prices. These five companies have the most at stake 10/19/2018 10:05:01 PM Trump wants drug commercials to include prices. These five companies have the most at stake Thu, 10/18/2018 - 20:00 cbaker_admin Fri, 10/19/2018 - 22:05 The Trump administration has unveiled a new policy that would require drug manufacturers to disclose their prices in television ads. The proposed legislation would have the biggest effect on five companies—Pfizer, AbbVie, Eli Lilly, Amgen, and Allergan—that were responsible for more than one-half of the drug ads customers saw on TV in the last 12 months, according to a STAT analysis of data provided by iSpot.tv. PhRMA, which has all five companies as members, is pushing for a voluntary alternative that would give patients some information about drug prices without requiring ads be updated each time a price changes—which would be costly for the manufacturers. Pfizer is the top TV ad spender, according to multiple data sets analyzed by STAT. It ran 37 unique ads in the past year, spending more than $600 million, iSpot estimates. (Click for more...) How much is too much? Acetaminophen overuse in the United States 10/19/2018 10:32:38 AM How much is too much? Acetaminophen overuse in the United States Fri, 10/19/2018 - 10:39 caldridgeyoung… Fri, 10/19/2018 - 10:32 A recent observational study detailing more than 4 years of acetaminophen use in the United States exposed the commonplace overuse of this widely accessible OTC analgesic, antipyretic, and antirheumatic drug. (Click for more...) AbbVie CFO Chase spearheaded its Abbott spinoff and Imbruvica buy—and now he's retiring 10/19/2018 10:28:28 AM AbbVie's chief financial officer, Bill Chase, is ready to retire next year after heading up the company's finances since it was born as an independent company in 2013. He'll be replaced by current controller Robert Michael. (Click for more...) NICE spurns Lilly’s breast cancer drug Verzenio in favor of rivals from Pfizer and Novartis 10/19/2018 10:14:11 AM Lilly's Verzenio for hormone receptor-positive, HER2-negative breast cancer seems to work just as well as Pfizer’s Ibrance and Novartis’ Kisqali, England's drug-price watchdog said, but Lilly didn't make a plausible case that it's more cost-effective. (Click for more...) Panel backing for key Shire drug beefs up Takeda's case for its $62B buyout 10/19/2018 10:06:22 AM Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market—and hoping to add blockbuster sales to a portfolio that’s at the heart of Takeda’s $62 billion buyout. (Click for more...) A bumper networking opportunity 10/19/2018 9:54:02 AM Marketer of the Year will celebrate its 25th anniversary at The Tower Hotel, London on Thursday 15 November, alongside Communications Team of the Year and the all-new Sales Awards. (Click for more...) Have you entered yet? 10/19/2018 9:19:04 AM International Clinical Researcher of the Year is celebrating its 20th anniversary in 2019. If ever there was a time to stand out against the competition and be remembered, it's now! (Click for more...) After Philippines safety scandal, Sanofi's Dengvaxia set for European approval 10/19/2018 9:15:41 AM Sanofi's beleaguered dengue vaccine is expected to win EU approval in December after a key committee voted in favor of the shot. A safety scandal in the Philippines triggered a WHO review that narrowed Sanofi's bid for European approval to patients who've been infected with dengue before. (Click for more...) Individuals from a wide array of companies flock to enter new awards scheme for medical and scientific professionals 10/19/2018 6:02:06 AM There are only two weeks to go until the 31 October deadline, don't miss it - get your entry in now!Highlighting this important area of work within the pharmaceutical industry, the new Medical & Scientific Excellence Awards are designed to recognise the outstanding achievements of medical and scientific professionals. (Click for more...) Keytruda/Inlyta combo shows significant survival benefit in kidney cancer trial 10/19/2018 5:30:23 AM A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer. (Click for more...) FDA advisory committee backs Shire’s prucalopride 10/19/2018 4:58:05 AM Shire’s prucalopride has taken a giant leap towards approval after winning the support of an FDA advisory committee for chronic idiopathic constipation. (Click for more...) US filing for ViiV’s two-drug, single pill HIV treatment 10/19/2018 4:39:34 AM ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV. (Click for more...) NICE rejects Lilly’s breast cancer drug Verzenios 10/19/2018 4:29:29 AM As it stands Eli Lilly’s Verzenios will not be routinely funded on the NHS for breast cancer, as cost-regulators have now issued draft guidelines rejecting the drug. (Click for more...) FiercePharmaAsia—China’s $1.3B vaccine fine; Lantus biosim retreat; Taiho’s VC fund 10/19/2018 4:28:03 AM China hands vaccine scandal culprit Changsheng a whopping $1.3 billion fine; Merck & Co. and Samsung Bioepis abandon development of a Lantus biosimilar on sales worries; Taiho injects another $250 million into its U.S.-based VC fund. (Click for more...) ESMO 2018 spotlights Merck’s Keytruda, Pfizer's Ibrance, AstraZeneca’s Lynparza and more 10/19/2018 3:13:21 AM This year’s ESMO will be packed with important data, and we at FiercePharma intend to keep you up to date on all the key developments for marketed drugs looking to sharpen their edge or expand into new uses. As the meeting kicks off, here are the studies we're tracking. (Click for more...) Walgreens and McLaren Health Care announce health services and pharmacy collaboration 10/18/2018 9:05:01 PM Walgreens and McLaren Health Care announce health services and pharmacy collaboration Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Walgreens and McLaren Health Care said Wednesday they have agreed to a strategic collaboration focused on health service and pharmacy offerings. McLaren, a fully integrated health network, said it will open a combination of several types of health service offerings in Walgreens locations around Michigan, such as retail health care clinics, urgent care facilities, and primary care centers. Pat Carroll, MD, Walgreens chief medical officer and group vice president, health care services and clinical programs, said: "Our collaboration with McLaren, demonstrates our ongoing commitment to create neighborhood health destinations that provide retail health services and patient care across the communities we serve." Under the agreement, Walgreens will operate select onsite pharmacies with the purchase of the prescription files and pharmacy inventory assets of McLaren pharmacies located in Michigan. Additionally, McLaren pharmacy patients and as McLaren Health Plan members, including McLaren employees, will be able to access Walgreens prescription services at any of the Walgreens owned pharmacies at McLaren locations or any neighborhood Walgreens stores. (Click for more...) CVS Health launches pilot program to combat diabetes in medically underserved Atlanta neighborhoods 10/18/2018 9:05:01 PM CVS Health launches pilot program to combat diabetes in medically underserved Atlanta neighborhoods Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 To tackle diabetes in medically underserved communities in the Tri-Cities area of Atlanta, CVS Health will launch a pilot project geared toward regions with chronically high rates of the disease. Through the collaboration, CVS Health and Rimidi will engage community-based organizations to ensure that at-risk residents can be identified for participation in the program. Lucienne Ide, Rimidi chair, says: "Like many major U.S cities, Atlanta has significant disparities in life-expectancy across the metropolitan area, from 71 years in medically underserved communities to 84 years in more affluent neighborhoods. Our collaboration with CVS Health will build on the foundation laid by community partners to address these needs and to bring health care services to people where they live and work." Rimidi and CVS Health will work with community organizations to enroll residents onto the Rimidi platform and engage them in diabetes education and support services offered through the pilot. The combination of hyper-local health care services via a pilot CVS Pharmacy location and digital services through Rimidi aims to decrease barriers to care and enhance the patient experience. CVS pharmacists and community certified diabetes educators intend to support participants throughout the continuum of care, providing additional touch points to address individual needs between primary care visits. (Click for more...) Rite Aid Offering Free Advisor Tool to Help Medicare Beneficiaries Choose Prescription Drug Coverage for 2019 10/18/2018 9:05:01 PM Rite Aid Offering Free Advisor Tool to Help Medicare Beneficiaries Choose Prescription Drug Coverage for 2019 Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Medicare-eligible customers can visit Rite Aid pharmacies nationwide to take advantage of free resources to help them select the right prescription drug plan or update existing coverage for 2019. Patients and caregivers can use Rite Aid's dedicated Medicare Advisor comparison tool to request the three lowest-cost prescription drug plans based on current prescriptions filled at Rite Aid. Patients can compare the estimated annual costs of various plans, including monthly premiums, brand and generic copays, and prescription drugs covered. There is no obligation to enroll or change plans. The annual Medicare Part D election period ends on December 7, 2018. Rite Aid participates in hundreds of Medicare prescription drug plan networks, and a complete list of all the Part D plans Rite Aid participates in is available upon request. The Medicare Advisor Tool is set by default to search for only those plans in which Rite Aid Pharmacy is an in-network pharmacy and eHealth is certified to sell in a customer's service area. Benefits, pharmacy network, and/or copayments/co-insurance may change on January 1 of each year, but customers must continue to pay their Part B premium. (Click for more...) What does the CVS-Aetna merger mean for Massachusetts? 10/18/2018 9:05:01 PM What does the CVS-Aetna merger mean for Massachusetts? Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Although CVS Health's $69 billion takeover of Aetna still requires some state approvals, the Department of Justice's approval of the deal clears a major hurdle. CVS has promised to keep Aetna's Hartford headquarters for the near future, while its own headquarters workforce of 5,500 in Woonsocket, RI, is expected to increase. Aetna is also proceeding with plans to add 250 jobs to its new consumer health and services office in Wellesley, MA. The deal is expected to spur a wave of vertical mergers, such as a Walmart-Humana merger, which was first rumored to be in the works this spring. The DOJ approval might also help prompt a health care merger in Massachusetts. For example, Boston-based hospital giant Partners HealthCare and Wellesley-based insurer Harvard Pilgrim are in talks about a combination, with a focus on improving the experience for patients while controlling costs. There is also widespread speculation about Amazon, which is entering the prescription drug business with its $1 billion purchase of Somerville's PillPack and working with Berkshire Hathaway and JPMorgan Chase on an unusual, Boston-based health care initiative headed by medical expert Atul Gawande. With the acquisition of Aetna, CVS Health becomes a stronger competitor to any Amazon venture, and it is more likely to remain an independent corporate force as mergers continue. (Click for more...) Connecticut insurance commissioner backs $69 billion CVS purchase of Aetna 10/18/2018 9:05:01 PM Connecticut insurance commissioner backs $69 billion CVS purchase of Aetna Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Connecticut Insurance Commissioner Katharine Wade on Wednesday approved the $69 billion acquisition of Hartford health insurer Aetna by CVS Health. The decision is contingent on the companies’ divesting Medicare prescription drug businesses to assure competition. Larry Merlo, chief executive officer of CVS, said state backing gives the merger a big push. "Connecticut is our primary regulator, so this approval represents a significant step forward for our companies," he noted. CVS has committed to keeping Aetna in Hartford for at least 10 years as part of its $69 billion acquisition of the health insurer. In her decision, Wade said CVS must report semiannually details of its business operations in Connecticut, including its integration of Aetna, any change in employment and other information. Aetna and CVS also must provide the state Insurance Department with details of the final purchase price after all adjustments used to complete the acquisition. (Click for more...) Minnesota accuses insulin makers of deceptive drug pricing 10/18/2018 9:05:01 PM Minnesota accuses insulin makers of deceptive drug pricing Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Minnesota Attorney General Lori Swanson has filed a lawsuit against Sanofi, Novo Nordisk, and Eli Lilly and Co., accusing the companies of deceptively raising prices for insulin. "Many people can't afford the price hikes but can't afford to stop taking the medication either," Swanson said. The lawsuit, filed in federal court in New Jersey, alleges that the drug makers set artificially high list prices for their products while offering rebates to PBMs in exchange for them covering the drug on behalf of health plans. The lawsuit also claims the drug companies were deceptive, listing the insulin prices so far from those net prices that they did not accurately approximate the true cost of insulin. For example, the price of insulin detemir recombinant (Levemir— Novo Nordisk) has risen from $120.64 per vial in 2012 to $293.75 in 2018; there have been similar price raises for insulin lispro recombinant (Humalog—Lilly) and insulin glargine recombinant (Lantus—Sanofi), according to Swanson. Sanofi and Eli Lilly said they believed the case was without merit, while Novo Nordisk said it was "committed to ethics and compliance in how we support patients." (Click for more...) J&J says putting drug prices in ads may scare away patients 10/18/2018 9:05:01 PM J&J says putting drug prices in ads may scare away patients Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Johnson & Johnson (J&J) said U.S. patients may avoid buying their medications if they see the prices in television advertisements. A proposal from the Trump administration forcing drugmakers to disclose the list price of any medication that costs more than $35 could discourage some from seeking treatment, executives from J&J said on an earnings conference call Tuesday. List prices on television ads "could be somewhat confusing and actually act as a deterrent to good, responsible health care and we just want to make sure that that doesn’t play out that way," J&J Chief Financial Officer Joseph Wolk said. Wolk said it supports transparency in drug pricing and the "spirit" of the Trump administration’s plan, but just not showing list prices in TV ads. "We just need to be careful of things such as list price alone," J&J’s head of pharmaceuticals, Jennifer Taubert, said on the call. "We would worry about patients not going to their doctor to seek care, not going in for their appropriate treatments." (Click for more...) Fall 2018 Unified Agenda: FDA's new regulatory work to advance health and safety 10/18/2018 9:05:01 PM Fall 2018 Unified Agenda: FDA's new regulatory work to advance health and safety Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 The U.S. government released on Wednesday the Fall 2018 Unified Agenda, which enables federal agencies to share the government's regulatory priorities with the public. "For the FDA," notes Commissioner Scott Gottlieb, MD, "the agenda reflects our ongoing commitment to protecting and promoting the public health through science-based decision-making that informs new regulations that advance the public health and promote innovative, efficient oversight of our key areas of influence." FDA's 2018 Strategic Policy Roadmap features four priorities that aim to further the agency's public health mission: reducing the burden of addiction crises that are threatening American families; leveraging innovation and competition to improve health care, broaden access, and advance public health goals; empowering consumers to make better and more informed decisions about their diets and health and expand the opportunities to use nutrition to reduce morbidity and mortality from disease; and strengthening FDA's scientific workforce and its tools for efficient risk management. According to Gottlieb, "The Fall 2018 Unified Agenda reflects our continued commitment to these priorities as well as other new steps to enable us to advance these and some additional goals." These include combatting nicotine addiction and preventing use among youth; modernizing nutrition claims, labels, and standards of identity; prioritizing medical device innovation and safety; and advancing drug safety, accessibility and affordability. Still, says Gottlieb, there is more work to be done, and in the coming year FDA will continue its efforts to fight the opioid epidemic, modernize product development through novel clinical trials, and advance antimicrobial development, among other goals. (Click for more...) Multidrug-resistant Salmonella Infantis infections linked to raw chicken products 10/18/2018 9:05:01 PM Multidrug-resistant Salmonella Infantis infections linked to raw chicken products Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 CDC reports that it is investigating an outbreak of Salmonella Infantis linked to raw chicken that has so far sickened 92 people in 29 states. No deaths have been reported in the outbreak, but 21 people have been hospitalized. According to epidemiologic and laboratory evidence, there are several types of raw chicken products from a number of sources that are contaminated with Salmonella and making people ill. CDC notes that "the outbreak strain of Salmonella was found in live chickens and in many types of raw chicken products, indicating it might be widespread in the chicken industry." As of yet, a single supplier of live chickens or of raw chicken products has not been found. The outbreak strain of Salmonella is resistant to multiple antibiotics that may be used to treat people with severe Salmonella infection, testing shows. (Click for more...) Beta-blocker use in pregnancy and the risk for congenital malformations 10/18/2018 9:05:01 PM Beta-blocker use in pregnancy and the risk for congenital malformations Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Researchers investigated the relationship between using beta-blockers to treat high blood pressure in early pregnancy and risk for major congenital malformations in offspring. The cohort study included data culled from Medicaid and health registries for 14,900 women with hypertensive pregnancies in the United States and 3,577 others in Finland, Sweden, Iceland, Norway, and Denmark. Respectively, 1,668 and 682 were exposed to beta-blockers during the first trimester. The pooled adjusted relative risk associated with this class of antihypertensive drugs was 1.07 for any major congenital malformation, 1.12 for any cardiac malformation, 1.37 for central nervous system malformations, and 1.97 for cleft lip or palate. The findings suggest that maternal use of beta-blockers during the first 3 months of a hypertensive pregnancy is not tied to a significant risk for overall malformations and cardiac malformations. (Click for more...) Shortened I.V. antibiotic course for uncomplicated, late-onset group B streptococcal bacteremia 10/18/2018 9:05:01 PM Shortened I.V. antibiotic course for uncomplicated, late-onset group B streptococcal bacteremia Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 Researchers wondered how often shorter courses of I.V. antibiotics are used instead of the standard 10-day treatment for babies with uncomplicated, late-onset group B Streptococcus (GBS) bacteremia and whether they are effective. The team used the Pediatric Health Information System database to identify 775 infants aged 7 days to 4 months who were hospitalized with GBS bacteremia during 2000–15. Nearly 80% of the patients were given a prolonged I.V. course of antibiotics, with about 20% undergoing shortened therapy as denoted by discharge after 8 days without a peripherally inserted central catheter charge. The rate of GBS recurrence was 2.3% for babies receiving prolonged therapy and 1.8% for those under the abbreviated regimen. The results of the retrospective cohort study indicate that it is not unusual for providers to prescribe shortened I.V. antibiotic courses in the setting of pediatric GBS bacteremia, with low rates of disease recurrence. (Click for more...) Michigan pharmacist refuses medicine to woman having miscarriage 10/18/2018 9:05:01 PM Michigan pharmacist refuses medicine to woman having miscarriage Wed, 10/17/2018 - 20:00 cbaker_admin Thu, 10/18/2018 - 21:05 An Ionia, MI, woman is demanding that the Meijer pharmacy in Petoskey, MI, implement a company-wide policy for how pharmacists should handle religious and moral objections to dispensing medication after she was denied a prescription to help complete a miscarriage. Rachel Peterson, 35, alleges a pharmacist at the Meijer store refused to fill her prescription for misoprostol in July because of his personal religious views. She says he also refused to transfer the prescription to another pharmacy. Misoprostol can be used to prevent stomach ulcers and also can be used to induce labor during pregnancy, to aid in the completion of a miscarriage and in the treatment of postpartum hemorrhage. When combined with another drug, it can be used to induce an abortion. The American Civil Liberties Union of Michigan sent a letter Tuesday on Peterson's behalf to Meijer, saying what the pharmacist did was discriminatory and violated the state's public accommodation laws. (Click for more...) 25% Dextrose Injection 10/18/2018 8:00:00 PM Drug: 25% Dextrose Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Aminophylline Injection 10/18/2018 8:00:00 PM Drug: Aminophylline Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Butorphanol Tartrate Injection 10/18/2018 8:00:00 PM Drug: Butorphanol Tartrate Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Calcium Chloride Injection 10/18/2018 8:00:00 PM Drug: Calcium Chloride Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Calcium Gluconate Injection 10/18/2018 8:00:00 PM Drug: Calcium Gluconate Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Cefazolin Injection 10/18/2018 8:00:00 PM Drug: Cefazolin Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Dobutamine Injection 10/18/2018 8:00:00 PM Drug: Dobutamine Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution 10/18/2018 8:00:00 PM Drug: Dorzolamide 2% and Timolol 0.5% Ophthalmic Solution, Revision Date: Fri, 19 Oct 2018 (Click for more...) Etoposide Solution for Injection 10/18/2018 8:00:00 PM Drug: Etoposide Solution for Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Labetalol Injection 10/18/2018 8:00:00 PM Drug: Labetalol Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Mannitol Injection 10/18/2018 8:00:00 PM Drug: Mannitol Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Phenytoin Sodium Injection 10/18/2018 8:00:00 PM Drug: Phenytoin Sodium Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Promethazine Injection 10/18/2018 8:00:00 PM Drug: Promethazine Injection, Revision Date: Fri, 19 Oct 2018 (Click for more...) Recombinant Zoster Vaccine (Shingrix) 10/18/2018 8:00:00 PM Drug: Recombinant Zoster Vaccine (Shingrix), Revision Date: Fri, 19 Oct 2018 (Click for more...) ESMO: Clovis bolsters Rubraca's PARP-leading prostate cancer bid with big-time response data 10/18/2018 6:28:31 PM Earlier this month, Clovis Oncology’s Rubraca picked up the FDA’s breakthrough designation in prostate cancer. And Friday, the company rolled out the data that helped it nab the agency’s distinction. (Click for more...) Merck's Keytruda, ready to challenge Bristol-Myers Squibb, posts kidney cancer combination win 10/18/2018 11:29:35 AM Merck’s Keytruda knows how to make an entrance. On Thursday, it hit the scene with kidney cancer combination data that could snag it a new indication months earlier than anticipated. (Click for more...) Insys drove ‘explosive' opioid painkiller sales by ‘owning’ physicians, Senate report reveals 10/18/2018 10:57:34 AM The U.S. Senate has released a 193-page report on Insys that provides a rare insider’s view of a company leaning on its physician partners to help drive sales. Among the documents the lawmakers gathered were emails from a sales manager demanding that reps recruit physicians to speak on behalf of the company’s opioid painkiller Subsys and threatening to withhold bonuses from them if they didn't score one prescription a day for the product. (Click for more...) AbbVie wards off another Humira biosim challenger with Fresenius Kabi settlement 10/18/2018 10:04:46 AM In a Humira patent deal with AbbVie, Fresenius Kabi will have to pay undisclosed royalties and can launch its biosim in Europe upon approval. In the U.S., the company will have to wait until September 2023 until it can launch. (Click for more...) GlaxoSmithKline’s job whacking touches U.S. consumer plant 10/18/2018 9:44:43 AM A GlaxoSmithKline consumer health products plant in Tennessee has had its ups and downs. Currently, it is having a down. The U.K.-based drugmaker will lay off nearly 100 employees at the facility in Memphis. (Click for more...) Gov’t to introduce tech standards for the NHS 10/18/2018 6:27:49 AM Health secretary Matt Hancock has unveiled his vision for technology in healthcare, which, he claims, will lay the foundation for a new generation of digital services able to meet the needs of clinicians, patients and managers. (Click for more...) NHS green light for Novartis skin cancer combo 10/18/2018 5:51:19 AM The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment. (Click for more...) Allergan to file ubrogepant for migraine early next year 10/18/2018 5:38:17 AM Allergan is gearing up to file its oral CGRP receptor ubrogepant in the US for the treatment of migraine, following the success and completion of two safety studies. (Click for more...) FDA releases additional NDMA/NDEA detection method 10/17/2018 8:05:01 PM FDA releases additional NDMA/NDEA detection method Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 A gas chromatography-tandem mass spectrometry method that uses liquid injection to detect the presence of the impurities N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) in valsartan drug products has been released by FDA. This method can be used on its own or with the combined gas chromatography-mass spectrometry (GC/MS) headspace method FDA recently released. The agency noted that, as with the previously issued methods, "this method should be validated by the user if the resulting data are used to support a required quality assessment of the API or drug product, or if the results are used in a regulatory submission." (Click for more...) Effect of theophylline as an adjunct to inhaled corticosteroids on COPD exacerbations 10/17/2018 8:05:01 PM Effect of theophylline as an adjunct to inhaled corticosteroids on COPD exacerbations Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 The results of a new study do not support the use of low-dose theophylline as adjunctive therapy to inhaled corticosteroids for the prevention of exacerbations among adults with chronic obstructive pulmonary disease (COPD), U.K. researchers report. The drug has been used as a bronchodilator to treat COPD for years; however, the higher doses that are required to achieve an effect are associated with adverse effects. In this study, more than 1,500 participants in the United Kingdom were randomized to receive low-dose theophylline (200 mg once or twice per day) to provide plasma concentrations of 1 to 5 mg/L (based on ideal body weight and smoking status) or placebo. The participants had a ratio of forced expiratory volume in the first second to forced vital capacity of less than 0.7 with at least two exacerbations in the previous year and were using an inhaled corticosteroid. There were 3,430 exacerbations in a 1-year period, with a mean number of 2.24 in the theophylline group and 2.23 in the placebo group. The researchers note that low-dose theophylline was not associated with a greater number of adverse reactions or serious adverse events, nor were there significant differences in the symptom profiles of serious adverse events between the theophylline and placebo groups. (Click for more...) Assessment of attitudes toward deprescribing in older Medicare beneficiaries 10/17/2018 8:05:01 PM Assessment of attitudes toward deprescribing in older Medicare beneficiaries Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 Doctors say older adults often balk at deprescribing, but new research demonstrates that they actually can be receptive to stopping some medicines. The study centered on nearly 2,000 Medicare beneficiaries aged 65 years or older and their responses to two questions as part of the National Health and Aging Trends Study. First, asked if they would be willing to discontinue one or more of their regular prescriptions if doing so was possible, 92% of the sample population responded in the positive. Second, about 67% agreed with the statement "I would like to reduce the number of medicines I am taking." The research also indicates that older patients who take at least six medicines are more open to both of those sentiments than are their counterparts who take fewer drugs. The findings are important, considering that potentially harmful or unnecessary medicine can result in adverse drug reactions, falls, hospitalization, and death in older patients. In an environment of patient-centered care and shared decisionmaking, however, the investigators say older adults are willing to wean off some medications at under their doctor's counsel. (Click for more...) UnitedHealth has bought another billion-dollar pharmacy business 10/17/2018 8:05:01 PM UnitedHealth has bought another billion-dollar pharmacy business Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 UnitedHealth Group said Tuesday that its Optum business has acquired Avella Specialty Pharmacy of Phoenix. The deal was disclosed in an earnings announcement. Terms of the agreement were not revealed; however, Avella will be brought into the OptumRx pharmacy-benefits unit. Avella was founded in 1996 under the brand The Apothecary Shops, and there are now locations in nine states and a home-delivery service. According to Drug Channels Institute data, Avella generated about $1.4 billion in revenue from prescription drugs in 2017, a 6% increase from the previous year. OptumRx also recently bought Genoa Healthcare, which operates pharmacies inside mental-health centers and provides telepsychiatry services. (Click for more...) Walgreens wants to be seen as a health care company, not just a pharmacy chain 10/17/2018 8:05:01 PM Walgreens wants to be seen as a health care company, not just a pharmacy chain Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 Walgreens wants to be seen as more than a pharmacy chain, having inked partnerships with numerous health care companies, including insurer Humana and diagnostics company LabCorp, to test new health services in some stores. "So you will see that in a few years our stores will be completely different and will give lot of prominence, even in front of stores, to health and beauty," Walgreens Boots Alliance CEO Stefano Pessina said Tuesday. Analysts note that investors want community pharmacies to reinvent their businesses as Amazon prepares to enter the prescription drug delivery business with its acquisition of online pharmacy, Pillpack. Despite all the concern in the market, Pessina said it is important to recognize that even Amazon understands it cannot be only online. He cited Amazon’s acquisition of Whole Foods affirming the e-commerce giant’s desire to get into brick-and- mortar retail. (Click for more...) Cost of blood pressure drug surges in U.S. after recall 10/17/2018 8:05:01 PM Cost of blood pressure drug surges in U.S. after recall Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 Prices for the blood pressure drug valsartan increased more than any other drug in the United States in September, following a recall of much of the drug's supply. Chinese pharmaceutical ingredient manufacturer Zhejiang Huahai Pharmaceuticals recalled valsartan from consumers in the United States in July after finding traces of a probable carcinogen. According to the National Average Drug Acquisition Cost \survey for last month, prices for 160 mg and 80 mg tablets of the drug more than doubled last month from August rates. The drug is the generic version of Novartis' Diovan. It has been in shortage since August, according to FDA. (Click for more...) Why Utah women haven't been able to get birth control directly from pharmacists--yet 10/17/2018 8:05:01 PM Why Utah women haven't been able to get birth control directly from pharmacists--yet Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 Frustration levels are rising in Utah, where legislators have signed—but not implemented—a new law allowing women to get contraception directly from a pharmacist. With the blessing of a state health department doctor, pharmacists—along with physicians and medical directors of local health departments—can provide the service under a limited standing order. Patients must undergo a health assessment, for which pharmacists may charge a fee, and provide documentation every 2 years to show that they have seen a primary care physician or women's specialty care provider before getting a new prescription. With a cost that is on par with getting prescription contraceptives through traditional avenues, the concept is appealing to many women in the state. However, they are being turned away when they try to sign on for the option, which is not expected to be available until next month or December. Bill sponsor Todd Weiler (R-Woods Cross) explains that lawmakers and other stakeholders are still trying to finalize rules for pharmacists and questions they should ask on the patient questionnaire. Once the law is finally implemented, adds Rep. Ray Ward (R-Bountiful), pharmacists will have to be brought up to speed—a task that he believes will fall to the Utah Pharmacy Association. (Click for more...) CVS Health encourages safe disposal of medicines ahead of National Prescription Drug Take-Back Day on October 27 10/17/2018 8:05:01 PM CVS Health encourages safe disposal of medicines ahead of National Prescription Drug Take-Back Day on October 27 Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 On October 27, National Prescription Drug Take-Back Day, CVS Health is encouraging consumers to safely dispose of unused prescriptions at safe medication disposal units in more than 750 CVS Pharmacy locations nationwide. An additional 900 disposal units have been distributed by CVS Health to such community locations as police departments. These units have collectively gathered more than 217 metric tons, or 480,000 pounds, of unwanted products. On October 27, community sites nationwide will host law enforcement take-back events. National Prescription Drug Take-Back Day is hosted biannually by DEA to help prevent drug addiction and overdose deaths. (Click for more...) How to avoid medication errors in hospitals 10/17/2018 8:05:01 PM How to avoid medication errors in hospitals Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 New guidelines from the American Society of Health-System Pharmacists offer pharmacists at health systems and hospitals best-practice recommendations to avoid medication errors. "Health-system pharmacists have the responsibility and expertise to lead and participate in multidisciplinary committees to examine and improve systems currently in place," the guidelines state. They focus on nearly a dozen focal points where medicine errors can be avoided, including patient admission, administration, monitoring, and patient discharge. To avoid adverse drug events at patient admission, the guidelines recommend obtaining a prescription history with pharmacy participation and conducting reconciliation. Recommendations to avoid administration errors at the bedside include checking patient allergies, obtaining two patient identifiers, and speaking with the patient about product indications and adverse events. To avoid monitoring errors, the guidelines propose training staff to identify common negative effects in patients and establishing protocols to respond to adverse reactions. Finally, to avoid errors during and after patient discharge, the guidelines recommend having a discussion with the patient featuring open-ended questioning and active listening, patient education focused on drugs such as insulin administration, and giving the patient an accurate list of medicines to be taken after discharge. The guidelines conclude that health systems and hospitals can reduce medication errors by redesigning systems, helping staff to make safe behavioral choices, and understanding employee behavior. (Click for more...) Get your influenza vaccination today and get rewarded at Kmart Pharmacy 10/17/2018 8:05:01 PM Get your influenza vaccination today and get rewarded at Kmart Pharmacy Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 As the influenza season gets underway, Kmart Pharmacy is encouraging its customers to get vaccinated against the disease. Members of Kmart's Shop Your Way (SYW) program are eligible to receive $5 cash back in SYW points for a no-cost influenza vaccine administered at a Kmart Pharmacy in the United States and Puerto Rico, and may also be eligible for Pharmacy Rewards. No copayment is necessary for the vaccination unless required by a patient's plan. Jennifer Speares Lehman, registered pharmacist and senior director for Kmart Pharmacy, says: "Our immunization-certified pharmacists truly care about the well-being of our members, and they do their very best to provide information and advice on health and wellness." Ranked No. 1 for customer satisfaction 2 years in a row, Kmart Pharmacy also worked directly with its partners to send additional doses of influenza and other immunizations to the South Carolina and North Carolina Kmart Pharmacies to support post-Hurricane Florence initiatives to vaccinate people. (Click for more...) By adding patents, drugmaker keeps cheaper copies of adalimumab out of U.S. 10/17/2018 8:05:01 PM By adding patents, drugmaker keeps cheaper copies of adalimumab out of U.S. Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 Cheaper copies of AbbVie's adalimumab (Humira) are rolling out across Europe this week after a key European patent for the drug expired Tuesday, but U.S. patients and insurers will have to wait to access less-expensive versions of the world's best-selling drug. AbbVie built up a formidable wall of patents that prevents the developers of biosimilars from launching their products in the United States. Companies have not revealed pricing for the adalimumab biosimilars, but they are expected to sell at a 10% to 25% discount in Europe's biggest drug markets, according to Alexandra Annis, an analyst at health care intelligence firm GlobalData. The main U.S. patent for adalimumab expired in 2016. But AbbVie has obtained more than 100 additional U.S. patents, a number legal experts describe as exceptional for a single drug. The shelf lives of those patents extend into the 2020s and 2030s. AbbVie cited these newer patents, which cover manufacturing processes and other aspects of the drug, in lawsuits to block the two biosimilar versions approved in the United States. Other companies say that has deterred them from bringing biosimilars to market quickly. (Click for more...) Paralyzing polio-like illness mainly affecting children confirmed in 22 states, CDC says 10/17/2018 8:05:01 PM Paralyzing polio-like illness mainly affecting children confirmed in 22 states, CDC says Tue, 10/16/2018 - 20:00 cbaker_admin Wed, 10/17/2018 - 20:05 CDC reported Tuesday that 127 confirmed or suspected cases of acute flaccid myelitis (AFM), a rare condition that primarily affects children and can cause paralysis, have been reported in the United States as of October 16. According to CDC's Nancy Messonnier, 62 cases have been confirmed in 22 states. "We understand that people, particularly parents, are concerned about AFM," said Messonnier, director of the National Center for Immunization and Respiratory Diseases. She added, "There is a lot we don't know about AFM, and I am frustrated that despite all of our efforts, we haven't been able to identify the cause of this mystery illness." As it is not yet clear how the disease spreads, federal health officials are now counting suspected cases in addition to confirmed to help them better anticipate any increases. Messonnier noted that the new data represents "a substantially larger number than in previous months this year." She also stressed that it is a rare condition, affecting less than 1 in 1 million individuals younger than age 18 years; but she said federal health officials hope to increase awareness of the symptoms to make sure parents seek prompt medical care if their children have a sudden onset of weakness or loss of muscle tone in their limbs. (Click for more...) Ceftazidime Injection 10/17/2018 8:00:00 PM Drug: Ceftazidime Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Daptomycin Injection 10/17/2018 8:00:00 PM Drug: Daptomycin Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Diltiazem Hydrochloride Injection 10/17/2018 8:00:00 PM Drug: Diltiazem Hydrochloride Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Furosemide Injection 10/17/2018 8:00:00 PM Drug: Furosemide Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Indomethacin Capsules 10/17/2018 8:00:00 PM Drug: Indomethacin Capsules, Revision Date: Thu, 18 Oct 2018 (Click for more...) Leucovorin Calcium Injection 10/17/2018 8:00:00 PM Drug: Leucovorin Calcium Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Pamidronate Disodium Injection 10/17/2018 8:00:00 PM Drug: Pamidronate Disodium Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Tobramycin Sulfate Injection 10/17/2018 8:00:00 PM Drug: Tobramycin Sulfate Injection, Revision Date: Thu, 18 Oct 2018 (Click for more...) Working through CEO swap, Pfizer plots job cuts in drive for 'simpler' structure 10/17/2018 3:34:28 PM A week after Pfizer unveiled a reshuffled executive team that'll report to incoming CEO Albert Bourla, the company says it's restructuring to simplify management and boost efficiency. And this latest move means job cuts—some 2% of Pfizer's global workforce of 90,200. (Click for more...) Health Sciences Campus to host Mountaineer Week events 10/17/2018 12:00:00 AM Mountaineer Week, WVU's annual celebration of West Virginia heritage and culture, will make a stop at the Health Sciences Campus on Wednesday, Oct. 24, from 11 a.m. – 1 p.m. on the Learning Center Green. (Click for more...) Piperacillin and Tazobactam Injection 10/16/2018 8:00:00 PM Drug: Piperacillin and Tazobactam Injection, Revision Date: Wed, 17 Oct 2018 (Click for more...) CMS proposes to require manufacturers to disclose drug prices in TV ads 10/16/2018 7:05:01 PM CMS proposes to require manufacturers to disclose drug prices in TV ads Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 CMS proposed on Monday that prescription drug manufacturers be required to post the Wholesale Acquisition Cost for drugs covered in Medicare or Medicaid in direct-to-consumer television ads. According to HHS Secretary Alex Azar, "This historic proposal is an important way to create new incentives for drug companies to start lowering their list prices, rather than raising them. President Trump's drug-pricing blueprint called for HHS to consider how to accomplish this goal, and now we are following through on this measure to better inform patients, help them lower their drug costs, and reduce unreasonable spending in Medicare and Medicaid." CMS said the proposed rule aims to give greater transparency to the prices set by drug manufacturers and would provide beneficiaries with the "information they need to make informed decisions based on cost, while concurrently providing a moderating force to counteract price increases." Under the proposal, the price that must be posted would be for a standard course of treatment for an acute medication, such as an antibiotic, or a 30-day supply of medication for a chronic condition that is taken every month. The posting would be included as a legible textual statement at the end of the drug ad, and HHS would keep a public list of drugs that did not follow this rule with their ads. An exception would be provided for prescription drugs with list prices that were less than $35 a month. CMS is requesting comment on whether the rule should apply to ads in other media forms, such as radio, magazines, newspapers, and social networking sites. Comments on the proposal are being accepted until December 17, 2018. (Click for more...) Unapproved pharmaceutical ingredients included in dietary supplements associated with FDA warnings 10/16/2018 7:05:01 PM Unapproved pharmaceutical ingredients included in dietary supplements associated with FDA warnings Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 Research shows that, despite FDA warnings, pharmaceutical ingredients that pose potential harm are still being used in OTC supplements. The quality improvement study examined the period of 2007–16, during which time 776 supplements were confirmed to include unapproved pharmaceutical ingredients. About 20% of the 776 supplements flagged contained multiple unapproved ingredients. Of 28 products that were found to be adulterated more than once, meanwhile, 19 included additional drug ingredients reported in their second or third warning. The investigators say this indication that products are still being used even after FDA warnings is alarming, considering that the regulator can only test a fraction of the products available on the market and given that more than one-half of all U.S. adults report taking dietary supplements. Unapproved drug ingredients in these supplements could cause serious adverse health effects from underlying health conditions, accidental misuse, overuse, or interaction with other medications, they warn. (Click for more...) Early clindamycin for bacterial vaginosis in pregnancy 10/16/2018 7:05:01 PM Early clindamycin for bacterial vaginosis in pregnancy Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 In France, the PREMEVA randomized controlled study explored whether treating bacterial vaginosis during pregnancy reduces the incidence of late miscarriage or spontaneous very preterm delivery. Single-course clindamycin was given to 943 participants with low-risk pregnancy, triple-course clindamycin was administered to 968, and 958 were given placebo. In a separate subtrial of women with bacterial vaginosis and high-risk pregnancy, 122 patients received single-course clindamycin and 114 received triple-course clindamycin. Women in both trials were recruited prior to 14 weeks' gestation. Among the low-risk pregnancies, 1.2% of the patients receiving treatment 1% of those taking placebo suffered late miscarriage or spontaneous very preterm birth. In the high-risk groups, meanwhile, the rate was 4.4% for those treated with triple-course clindamycin and 6% for those treated with single-course clindamycin. No severe adverse events were reported for any of the treatment groups. The investigators conclude that systematic screening for and treatment of bacterial vaginosis during low-risk pregnancy does not appear to curb the risk of late miscarriage or spontaneous very preterm birth. "In the context of increasing recognition that indiscriminate antibiotic use increases the risk of resistance and might be associated with long-term risks, antibiotic prevention of preterm delivery in women with low-risk pregnancies who have bacterial vaginosis should be reconsidered," they write. (Click for more...) New value assessment framework needed for biosimilars, white paper argues 10/16/2018 7:05:01 PM New value assessment framework needed for biosimilars, white paper argues Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 A new framework for assessing the value of biosimilars is needed, according to a new white paper authored by Xcenda for the Biosimilars Forum. The white paper contends that none of the existing value assessment frameworks are completely suited to assessing the value of biosimilar medicines. It also notes that because biosimilars are priced below their reference products, they could drive reference products' prices lower, potentially contributing to increased patient access. However, without strategic policy efforts, U.S. patients may not feel the benefit of lower copays for biosimilars. The paper identifies five factors that will be important to consider in developing value assessments of biosimilars: lower drug acquisition costs, improved adherence, earlier treatment, patient experience, and development and innovation. (Click for more...) CVS Health CEO Larry Merlo doesn't want to leave any 'white space' for Amazon to disrupt 10/16/2018 7:05:01 PM CVS Health CEO Larry Merlo doesn't want to leave any 'white space' for Amazon to disrupt Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 CVS Health CEO Larry Merlo discussed his company's plans Monday in an interview with David Rubenstein, president of the Economic Club of Washington, DC. The company spends a lot of time listening to its customers to understand what they are not happy about and filling their unmet needs, he said. "So that's what we focus on as an organization, with the goal being: Don't leave any white space for Amazon to disrupt," Merlo said. CVS is trying to become a disruptive force itself with its $69 billion acquisition of Aetna. With the deal, CVS wants to manage chronic conditions such as diabetes at its MinuteClinics. They also want to steer people into these walk-in clinics and away from more expensive sites such as emergency rooms. The Department of Justice last week gave the deal preliminary approval. CVS still needs states' approval. Merlo said Monday the company is in the "home stretch" of that process. (Click for more...) Drugmakers funnel millions to lawmakers 10/16/2018 7:05:01 PM Drugmakers funnel millions to lawmakers Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 Dozens of drugmakers have contributed approximately $12 million to hundreds of members of Congress. Since the beginning of 2017, 34 lawmakers have each received more than $100,000 from pharmaceutical companies. In the past decade, Congress has received $79 million from 68 pharma political action committees run by employees of companies that make drugs. By June 30, 52 PACs funded by pharmaceutical companies and their trade organizations had given about $12 million to members of Congress for this election cycle. Drugmakers also spend millions of dollars lobbying members of Congress directly and give to patient advocacy groups, which provide patients to testify on Capitol Hill and organize social media campaigns on drugmakers' behalf. (Click for more...) Combustible and electronic tobacco and marijuana products in hip-hop music videos 10/16/2018 7:05:01 PM Combustible and electronic tobacco and marijuana products in hip-hop music videos Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 Popular hip-hop music videos often show combustible and electronic tobacco and marijuana use, according to new research. "The confluence of hip-hop's broad appeal, use of branded products by influential artists, and growing interest in electronic products and marijuana all contribute to the important public health concern of tobacco and marijuana use," the authors write. The researchers conducted an analysis of the top 50 songs from 2013 to 2017 of Billboard magazine's weekly Hot R&B/Hip-Hop Songs with videos that included the appearance or use of combustible tobacco and marijuana products; appearance of exhaled smoke or vapor without an identifiable source product; appearance or use of electronic tobacco and marijuana products; tobacco or marijuana brand placement; or the appearance or use of combustible and electronic tobacco and marijuana by the main or featured artist. The data indicate that the proportion of top hip-hop videos that included the appearance of combustible use, electronic use, or smoke or vapor ranged from about 40% to nearly 51%. In addition, the appearance of branded combustible and electronic products increased substantially during the study period. The authors suggest that "future regulation that directly addresses the often co-occurring appearance and marketing of tobacco, marijuana, and electronic products in music videos would limit exposure to their use and could reduce the burden of tobacco and marijuana use." (Click for more...) Using clinical pharmacists to improve your emergency department 10/16/2018 7:05:01 PM Using clinical pharmacists to improve your emergency department Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 Emergency medicine (EM) clinical pharmacists can alleviate staffing shortages, enhance patient safety, boost efficiency, and generate significant cost savings, according to the authors of a recent article in the American Journal of Emergency Medicine. EM clinical pharmacists can help take medication burdens off other staff members and streamline pharmacotherapy-related care in a busy emergency department, they noted. "Instead of physicians or nurses having to call the central pharmacy with questions, the pharmacist is right in the department and can provide consultation at the bedside." The researchers added that EM clinical pharmacists can improve patient safety by reducing many common medication errors, "especially those containing multiple medication orders and those prescribed by EM residents." In addition, opportunities for EM clinical pharmacists to increase efficiency range from drug therapy monitoring after the administration of medication to patient education at the time of discharge. These pharmacists can also reduce costs—a study cited in the authors' research found that 9,568 interventions by EM clinical pharmacists over a 6-month period generated cost savings of $845,592. The researchers said that EM clinical pharmacists can also improve hospitals organizationally by acting as the pharmacy liaison between departments. (Click for more...) Q&A: Women in pharmacy lead through practice 10/16/2018 7:05:01 PM Q&A: Women in pharmacy lead through practice Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 As October 12 was National Women Pharmacists Day, Drug Store News conducted a Q&A with current and aspiring women pharmacists to gain their perspective on challenges and opportunities in the industry. Jennifer Zilka, group vice president of Good Neighbor Pharmacy's Field Programs and Services, noted that the number of women in pharmacy has increased significantly over the last decade, adding that more than one-half of student pharmacists today are women. "At Good Neighbor Pharmacy, we're optimistic about the overall state of the profession, including the growing number of female pharmacists joining the workforce," she said. However, Deirdre Myers, pharmacy instructor at Ohio Northern University, pointed to the challenges facing female pharmacy owners, including work-life balance. She suggested that pharmacy owners explore co-ownership, which could help them manage the amount of responsibility associated with operating a business. "I'd encourage every pharmacy owner to find ways to explore co-ownership and co-parenting to maintain the right level of work-life balance," she said. Even though there are challenges, Jessica Satterfield, student pharmacist at the University of Iowa, said she is "incredibly optimistic about a future in pharmacy ownership." She suggested more mentorship programs, which she said are "an excellent opportunity to learn how to open and operate a business, including learning how to manage financials, develop employees and drive profitability—all while operating at the top of your license." (Click for more...) Pharma industry pushes back against required listing of drug prices in TV ads 10/16/2018 7:05:01 PM Pharma industry pushes back against required listing of drug prices in TV ads Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 The pharmaceutical industry is signaling resistance to a Trump administration plan to require that the list price be included for most drugs in television ads. Instead, the Pharmaceutical Research and Manufacturers of America (PhRMA)on Monday announced that major drugmakers would voluntarily include price-related information in television ads by directing consumers to websites where they can find information on list prices and costs. That action falls short of the proposed HHS rule to mandate the disclosure of list prices in television ads, rather than referring consumers elsewhere for information. Drugmakers say that providing only the list price would confuse and mislead consumers, who may think they have to pay more than they actually would. Critics also say the rule runs afoul of the First Amendment free-speech protections, and that a legal challenge is likely. PhRMa said its voluntary effort would help patients make more informed decisions. They will also create a website with information about cost and financial help. "We believe this is the right thing to do and is an important step toward providing patients with the information they want," said Stephen Ubl, president and CEO of PhRMA. (Click for more...) FDA's new steps to modernize drug development, improve efficiency, and promote innovation of targeted therapies 10/16/2018 7:05:01 PM FDA's new steps to modernize drug development, improve efficiency, and promote innovation of targeted therapies Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 FDA issued on Monday two guidance documents aimed at providing drug developers more clarity and direction for the next generation of therapies and treatments. The first, Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment, is a draft guidance the agency is developing to help sponsors planning to use minimal residual disease as a biomarker in clinical trials of drugs or biologics to treat certain blood cancers. The second, Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease, is a final guidance about finding treatments that address the underlying molecular changes that cause or contribute to diseases. The guidance includes an approach for drug developers to enroll patients based on the identification of rare variants into clinical trials for targeted therapies and discusses the evidence required to demonstrate efficacy for a number of molecular subsets within a particular disease. "Today's guidance documents are part of the FDA's science-based mission to modernize clinical trials and advance the development of safe and effective drugs and biologics for the American public," Gottlieb noted. (Click for more...) Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research 10/16/2018 7:05:01 PM Harvard and the Brigham call for more than 30 retractions of cardiac stem cell research Mon, 10/15/2018 - 20:00 cbaker_admin Tue, 10/16/2018 - 19:05 Brigham and Women's Hospital and Harvard Medical School say that 31 papers from the lab of Piero Anversa, MD, should be retracted from medical journals. These papers, based on the idea that the heart contains stem cells that can regenerate cardiac muscle, "included falsified and/or fabricated data," the institutions say. In 2017, the hospital agreed to a $10 million settlement with the U.S. government over allegations Anversa and two colleagues' work had been used to fraudulently obtain federal funding. Anversa and Annarosa Leri, MD, have had at least one paper already retracted, and one subject to an expression of concern. The researchers unsuccessfully sued Harvard and the Brigham for alerting journals to problems in their work in 2014. Anversa's lab closed in 2015; and Anversa, Leri, and colleague Jan Kajstura, PhD, no longer work at the hospital. The U.S. Office of Research Integrity has not made a finding in the case. Anversa previously corrected eight of his papers, many for failing to disclose conflicts of interest. Various research teams have been unable to reproduce the results claimed in Anversa's work involving "c-kit cells." Some scientists have tried to inject c-kit cells into damaged hearts and saw only mixed results. (Click for more...) Are Drug-Drug Interactions Today’s Biggest Health Threat? 10/16/2018 5:13:19 PM The use of prescription medicines is sharply on the rise. Over the past decade, the number of adults taking over-the-counter medicines has sunk, while the number of prescription drug users has increased by more than 30 percent. While pharma research has changed millions of lives for the better, the increased risk of adverse drug reactions […] (Click for more...) Human Cells + Tech = Accelerated Drug Development and Treatment 10/16/2018 4:13:13 PM Some scientific advancements can be both awe-inspiring and just a little creepy at the same time. In the world of pharma and medicine, this applies to some newer approaches that are melding living cells with high-tech to do some wonderful things. Two such advances, which made the short list for BiopharmaTrend.com’s top trends in pharmaceutical […] (Click for more...) Text message reminders shorten time to prescription pick-up at independent pharmacies 10/16/2018 1:20:26 PM Text message reminders shorten time to prescription pick-up at independent pharmacies Tue, 10/16/2018 - 13:23 caldridgeyoung… Tue, 10/16/2018 - 13:20 Patients who get their prescriptions filled at independent pharmacies may benefit from text message reminders and pick up their prescriptions sooner, according to a study published online in the Journal of the American Pharmacists Association (Click for more...) Resistance to HIV medications rare during preexposure prophylaxis 10/16/2018 8:53:14 AM Key Point:Primary drug resistance to either tenofovir disoproxil fumarate (TDF) and/or emtricitabine (FTC, Truvada—Gilead) was rare in people who acquired HIV infection while enrolled in a preexposure prophylaxis (PrEP) trial, according to an analysis of data published in AIDS. (Click for more...) Extended-pulsed fidaxomicin a good option for C. difficile infections 10/16/2018 8:42:13 AM Key Point:Use of extended-pulsed fidaxomicin (Dificid–Merck) was superior to standard-dose vancomycin when given to older patients with Clostridium difficile infections with respect to sustained clinical cure rates 30 days after the end of treatment, according to results of a trial published in Lancet Infectious Diseases. (Click for more...) Using data for good to solve humanitarian issues 10/16/2018 5:18:28 AM Researchers are increasingly using their domain expertise to tackle many of the world’s problems such as hunger, pandemics and other societal issues. When I worked for a pharma company I was continually surprised experienced pharmacologists could tell me which toxicology events in animals were predictive of human responses and which events could be safely ignored. […] (Click for more...) How Drug Repurposing Is Revitalizing the Pharma Industry 10/16/2018 4:57:00 AM The average expense of bringing a new drug to market has increased by more than 200 percent since the 1990s, with development costs regularly running into the billions. As pharma revenues continue to sink below the costs of creating commercially viable drugs, a growing number of developers are exploring a different approach: seeking out additional […] (Click for more...) Drawbacks of Consumer Genetic Testing – And What Pharma Can Do To Make It Better 10/16/2018 4:36:37 AM Genetic testing has become a big hit with consumers. Companies like Ancestry.com and 23andMe flood the airwaves with commercials about the joy of using DNA testing to find out about your heritage. But another reason genetic testing is attracting consumers is because it also can tell people about some of their genetic health risks. The […] (Click for more...) The Delicate Balance of Drug Risks vs. Benefits 10/16/2018 4:16:08 AM For many people, taking medication is a regular part of their daily routine, and these medicines are relied upon to treat disease and improve health. The benefits of medicines are the helpful effects you get when you use them, such as the lowering blood pressure, curing infection, or relieving pain. Although medicines can make you […] (Click for more...) Acetylcysteine Oral and Inhalation Solution 10/15/2018 8:00:00 PM Drug: Acetylcysteine Oral and Inhalation Solution, Revision Date: Tue, 16 Oct 2018 (Click for more...) Buprenorphine Hydrochloride Injection 10/15/2018 8:00:00 PM Drug: Buprenorphine Hydrochloride Injection, Revision Date: Tue, 16 Oct 2018 (Click for more...) Cefotaxime Sodium Injection 10/15/2018 8:00:00 PM Drug: Cefotaxime Sodium Injection, Revision Date: Tue, 16 Oct 2018 (Click for more...) Dexrazoxane Injection 10/15/2018 8:00:00 PM Drug: Dexrazoxane Injection, Revision Date: Tue, 16 Oct 2018 (Click for more...) Epinephrine Auto-Injectors 10/15/2018 8:00:00 PM Drug: Epinephrine Auto-Injectors, Revision Date: Tue, 16 Oct 2018 (Click for more...) Hydromorphone Hydrochloride Injection 10/15/2018 8:00:00 PM Drug: Hydromorphone Hydrochloride Injection, Revision Date: Tue, 16 Oct 2018 (Click for more...) Lidocaine Injection 10/15/2018 8:00:00 PM Drug: Lidocaine Injection, Revision Date: Tue, 16 Oct 2018 (Click for more...) Morphine Injection 10/15/2018 8:00:00 PM Drug: Morphine Injection, Revision Date: Tue, 16 Oct 2018 (Click for more...) Trifluoperazine Tablets 10/15/2018 8:00:00 PM Drug: Trifluoperazine Tablets, Revision Date: Tue, 16 Oct 2018 (Click for more...) Ohio Board of Pharmacy wants to ban Kratom 10/15/2018 6:05:01 PM Ohio Board of Pharmacy wants to ban Kratom Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 The Ohio Board of Pharmacy wants to ban the herbal supplement Kratom, an all-natural product that comes from the Kratom plant. Hemptations owner E.R. Beach says his customers have been requesting Kratom for more than 7 years and tell him it helps with anxiety and pain relief. However, in a report the Ohio Board of Pharmacy found Kratom has a high potential for abuse; has no accepted medical use in treatment in the state; lacks accepted safety for use in treatment under medical supervision; and poses a risk to the public health of the citizens in this state. Beach says the board has no legal authority to lawfully ban Kratom, but it can make a recommendation to the state Legislature to make it illegal. "If the state of Ohio makes this substance illegal then we won't sell it anymore," Beach says. (Click for more...) HHS awards $2.34 billion in grants to help Americans access HIV/AIDS care and medication 10/15/2018 6:05:01 PM HHS awards $2.34 billion in grants to help Americans access HIV/AIDS care and medication Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 HHS reported Thursday that about $2.34 billion in Ryan White HIV/AIDS Program grants were awarded to cities, counties, states, and local community-based organizations in fiscal year 2018. The funding, awarded through the Health Resources and Services Administration (HRSA), is used to support a system of HIV primary medical care, medications, and key support services for more than 500,000 people living with HIV. "New medical advances and broader access to treatment have helped transform HIV/AIDS from a likely death sentence into a manageable chronic disease," said HHS Secretary Alex Azar. "The Ryan White HIV/AIDS Program is an important way to ensure that these life-saving treatments reach the Americans who need them." The program awards included about $624.3 million to 52 metropolitan areas to provide core medical and support services living with HIV; $1.4 billion to 59 states and territories to improve the quality, availability, and organization of HIV health care and support services and for the AIDS Drug Assistance Program; $181.9 million to 351 local, community-based organizations to provide core medical and support services to people living with HIV; and approximately $70.3 million to 115 local community-based organizations across the country to provide family-centered comprehensive HIV care and treatment for women, infants, children, and youth. (Click for more...) FDA expands investigation of e-cigarette marketing to youth 10/15/2018 6:05:01 PM FDA expands investigation of e-cigarette marketing to youth Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 FDA is investigating whether more than 40 e-cigarette products, including some flavored e-cigarette products, are being illegally marketed and outside the agency's current compliance policy. On Friday, FDA sent letters to 21 e-cigarette companies about the products. FDA Commissioner Scott Gottlieb, MD, said: "Companies are on notice—the FDA will not allow the proliferation of e-cigarettes or other tobacco products potentially being marketed illegally and outside of the agency's compliance policy, and we will take swift action when companies are skirting the law. Given the explosive growth of e-cigarette use by kids, we're committed to taking whatever measures are appropriate to stem these troubling use trends. ... If products are being unlawfully marketed and outside the FDA's compliance policy, we'll act to remove them. FDA's letters request that the e-cigarette companies supply information about the products in question, including proof that the product is a deemed product that was on the market as of August 8, 2016 and has not been modified since that time. The letters are part of a series of actions FDA has taken in recent months to target the illegal sales of e-cigarettes to youth as well as the youth-friendly marketing and appeal of the products. (Click for more...) Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus 10/15/2018 6:05:01 PM Efficacy and safety of ustekinumab in patients with active systemic lupus erythematosus Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 Although the monoclonal antibody ustekinumab is indicated for psoriasis, psoriatic arthritis, and Crohn disease, researchers thought it might also be effective in treating systemic lupus erythematosus. The hypothesis centers around the drug's select targeting of interleukin-12 and -13, which have a suspected role in the pathology of the disease. Based on this rationale, an international team of investigators performed a Phase II study to test the theory in adult patients with systemic lupus erythematosus. A total of 60 participants whose symptoms persisted despite conventional treatment were randomized to blinded treatment with ustekinumab, administered as an initial I.V. infusion followed by subcutaneous injections every 8 weeks. Another 42 patients were assigned to matched treatment using placebo. All participants continued to receive usual care for systemic lupus erythematosus during the trial period. The main outcome was the proportion of patients with a score of 4 on a disease activity responder index at week 24. That endpoint was achieved by 62% of the ustekinumab group and 33% of the controls. Meanwhile, the share of participants experiencing one or more adverse events was 78% for ustekinumab, which is on par with its safety profile for other conditions, and 67% for placebo-takers. The evidence supports continued development of ustekinumab as a novel intervention for systemic lupus erythematosus. (Click for more...) Vaccine exemptions up for third year in a row, CDC reports 10/15/2018 6:05:01 PM Vaccine exemptions up for third year in a row, CDC reports Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 CDC researchers say the share of children starting kindergarten with exemptions to vaccine requirements hit a median of 2.2% students per state in 2017–18. The estimate is up from 2.0% during the previous academic year and from 1.9% during 2015–16. Some 7.6% of kindergarteners in Oregon entered school with an exemption to one or more vaccines, more than in any other state or territory. The greatest compliance, meanwhile, was in Mississippi, where the exemption rate was just 0.1%. According to the data, which was published in Morbidity and Mortality Weekly Report, kindergarten students this year were most protected against diphtheria, tetanus, and acellular pertussis (DTaP), with a median coverage rate of 95.1%. Median uptake was 93.8%, meanwhile, for varicella and 94.3% for measles, mumps, and rubella (MMR) vaccine. Most undervaccinated students, however, did not have an exemption. (Click for more...) Impatient patients turn to online 'buyers club' for new drugs 10/15/2018 6:05:01 PM Impatient patients turn to online 'buyers club' for new drugs Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 A growing number of patients worldwide who are facing delays getting novel drugs are turning to Amsterdam-based online broker Social Medwork to self-import medicines from abroad. The group—which is registered with the Dutch Ministry of Health as a medicines intermediary—says it is the only organization focused on supplying newly approved branded drugs for diseases such as cancer, migraine, and multiple sclerosis. Its customers can place orders online legally as long as they have a prescription and a doctor's note stating that the drug is intended solely for personal use. In the past 18 months, the group has supplied more than 3,000 patients in 70 countries, including Britain, where drug delays could be exacerbated by Brexit. It currently has fewer customers in the United States given the relatively fast drug approvals in the country, but there was a jump in U.S. demand last year for the amyotrophic lateral sclerosis drug edaravone (Radicut/Radicava—Mitsubishi Tanabe Pharma), which was initially approved in Japan. (Click for more...) Sears files for Chapter 11 bankruptcy 10/15/2018 6:05:01 PM Sears files for Chapter 11 bankruptcy Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 Sears Holdings Corp. filed for Chapter 11 bankruptcy protection early Monday, hoping to use the filing in federal court in New York to slash its debts and stay in business at least through the holidays. As part of the reorganization plan, Sears has negotiated a $300 million loan from Wall Street lenders to help keep its shelves stocked and employees paid. The company said its controlling shareholder, Edward Lampert, has stepped down as CEO but will remain chairman. Sears further confirmed that it would close 142 money-losing stores near the end of December, with liquidation sales expected to start shortly. Those closings are on top of the 46 stores that are expected to be shuttered by next month. The company operates about 700 Sears and Kmart stores and employs about 70,000 people at present. The Chapter 11 filing came before the company was required to repay $134 million in loans later today. Sears’s restructuring plan is expected to be presented to the judge Monday following days of marathon negotiations between the retailer and its bank lenders. The banks are the principal lenders on a $1.5 billion asset-backed credit line, secured by store inventory as well as credit-card and pharmacy receivables. Much of that credit line has been drawn down, leaving Sears desperate for cash as the holidays approach and a Monday loan-repayment deadline loomed. (Click for more...) Secretary Azar's community pharmacy and patient roundtable in Pittsburgh 10/15/2018 6:05:01 PM Secretary Azar's community pharmacy and patient roundtable in Pittsburgh Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 HHS Secretary Alex Azar and CMS Chief of Staff Paul Mango participated on Friday in a roundtable discussion at Spartan Pharmacy in Pittsburgh. The roundtable, which focused on the recently signed legislation to ban pharmacy gag clauses, also included community pharmacists and patients. At the meeting, Azar highlighted the importance of patients asking their pharmacists if they are getting the best deal on prescription medications, and he listened to the participants' concerns about health care and their ideas on how to reduce prescription drug costs. (Click for more...) Winn-Dixie opening mobile pharmacy location in Panama City 10/15/2018 6:05:01 PM Winn-Dixie opening mobile pharmacy location in Panama City Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 In the wake of Hurricane Michael, Winn-Dixie is deploying a mobile pharmacy in Panama City, FL. Located at 3621 US Highway 231 North, the pharmacy will have vaccines, prescription refills, and transfers starting on October 14. "Winn-Dixie is proud to be part of the Panama City community and the Hurricane Michael relief efforts as we join our neighbors in the recovery process from the effects of this devastating storm," said Anthony Hucker, president and CEO of Southeastern Grocers. "We know medications, water and ice are essential items for many, and we will continue to work hand-in-hand with our vendor partners and local organizations to ensure we are supporting Panama City residents during this difficult time of recovery." The mobile pharmacy will also be providing free water and ice, along with three other locations in Panama City Beach, Parker, and Lynn Haven. (Click for more...) FDA sets record for number of generic drug approvals again 10/15/2018 6:05:01 PM FDA sets record for number of generic drug approvals again Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 FDA announced that it has approved and tentatively approved the most amount of generic drugs in FY 2018 than ever before. In FY 2018, FDA made 971 total approvals, compared with 937 total approvals in FY 2017. About 12% of the total drug approvals in FY 2018 were for complex generics, and three new approvals received a Competitive Generic Therapy designation, which helps expedite the development of generic versions of products that lack competition. FDA Commissioner Scott Gottlieb said the agency has made strides this year, but there is more that can be done. "We'll continue taking additional steps to help ensure patients have access to the drugs they need by making generic drug approval more efficient and predictable," he said. "We are doing this by continuing to streamline the generic drug review process to get more competitors on the market. We have found that having three or more generic competitors brings prices down more sharply than with only one or two generic competitors." (Click for more...) Specialty pharmacies toe the line between access, cost, and outcomes 10/15/2018 6:05:01 PM Specialty pharmacies toe the line between access, cost, and outcomes Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 Specialty pharmacies are under increasing pressure to find innovative ways to manage the astronomical costs of specialty drugs, while simultaneously providing the clinical expertise and ongoing support that these drugs require. One tactic specialty pharmacies are employing is establishing alliances or making acquisitions to expand access to specialty drugs. The idea is that providing access to these drugs and expert clinical support will help patients be more compliant with their drug regimens, thus reducing health care expenditures that are often linked to poor outcomes. For US Bioservices, a longtime player in the specialty pharmacy arena, being acquired by AmerisourceBergen in 2003 enabled the company to continue to expand its specialty services and therapies that it offers patients, and to engage more directly with pharmaceutical manufacturers. Helping patients understand financial assistance programs is another strategy that specialty pharmacies are employing to lower drug costs. "If patients can afford their medicines, there is a greater likelihood that they will fill their prescriptions and stay adherent to their drug regimens," said Joy Gilbert, US Bioservices' vice president of operations. She said US Bioservices connects patients with resources they may be unaware of, and helps patients with their paperwork and benefit coverages to ensure they can afford their medication. Specialty pharmacies are also developing tailored disease-state programs that are intended to manage high drug costs. For example, Walgreens' ConnectedCare is a disease-state tailored program in which patients are automatically enrolled. A pharmacist consults with the patient during an initial assessment of a new regimen as well as each time the patient needs a refill. (Click for more...) Jurors in deadly meningitis-outbreak trial will learn of profits reaped by drug executive 10/15/2018 6:05:01 PM Jurors in deadly meningitis-outbreak trial will learn of profits reaped by drug executive Sun, 10/14/2018 - 20:00 cbaker_admin Mon, 10/15/2018 - 18:05 U.S. District Judge Richard G. Stearns has ruled that federal prosecutors will be able to tell jurors about the estimated $20 million in profits collected by the vice president of a drug company blamed for a deadly 2012 fungal meningitis outbreak. Stearns denied a motion by Gregory Conigliaro's lawyers to bar the prosecutors from disclosing the amount earned by Conigliaro in his upcoming trial on conspiracy charges. Conigliaro is one of six defendants going on trial Monday in U.S. District Court in Boston, Mass. on charges ranging from racketeering to mail fraud. The defendants were employees of the New England Compounding Center, the company that sold thousands of vials of fungus laden medications to health facilities across the country. The outbreak killed 76 patients among nearly 800 that were sickened. Tennessee was the second-hardest hit state by the outbreak, with 153 illnesses and 16 deaths, according to CDC. (Click for more...) 23.4% Sodium Chloride Injection 10/14/2018 8:00:00 PM Drug: 23.4% Sodium Chloride Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Bumetanide Injection 10/14/2018 8:00:00 PM Drug: Bumetanide Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Bupivacaine Injection 10/14/2018 8:00:00 PM Drug: Bupivacaine Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Chlorothiazide Sodium Injection 10/14/2018 8:00:00 PM Drug: Chlorothiazide Sodium Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Fluorescein Sodium Ophthalmic Strips 10/14/2018 8:00:00 PM Drug: Fluorescein Sodium Ophthalmic Strips, Revision Date: Mon, 15 Oct 2018 (Click for more...) Haloperidol Tablets 10/14/2018 8:00:00 PM Drug: Haloperidol Tablets, Revision Date: Mon, 15 Oct 2018 (Click for more...) Orphenadrine Citrate Injection 10/14/2018 8:00:00 PM Drug: Orphenadrine Citrate Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Potassium Phosphate Injection 10/14/2018 8:00:00 PM Drug: Potassium Phosphate Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Protamine Injection 10/14/2018 8:00:00 PM Drug: Protamine Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Pyridoxine Hydrochloride Injection 10/14/2018 8:00:00 PM Drug: Pyridoxine Hydrochloride Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Ropivacaine Injection 10/14/2018 8:00:00 PM Drug: Ropivacaine Injection, Revision Date: Mon, 15 Oct 2018 (Click for more...) Sterile Water for Injection - Small Volume Vials 10/14/2018 8:00:00 PM Drug: Sterile Water for Injection - Small Volume Vials, Revision Date: Mon, 15 Oct 2018 (Click for more...) Thiothixene Capsules 10/14/2018 8:00:00 PM Drug: Thiothixene Capsules, Revision Date: Mon, 15 Oct 2018 (Click for more...) CVS Health and Goodwill offer workforce training at 'mock' pharmacy in Baltimore 10/12/2018 3:05:01 PM CVS Health and Goodwill offer workforce training at 'mock' pharmacy in Baltimore Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 A "mock pharmacy" at the Baltimore headquarters of Goodwill Industries is central to a new workforce development program officially launched Thursday through a partnership between CVS Health, Goodwill, and Baltimore City Community College. So far, eight students have completed a 16-week program to train people for in-demand jobs as pharmacy technicians. The students, who were given certificates Thursday, are being placed in area CVS stores. For CVS Health, the initiative is one of the latest of its workforce development programs aimed at underserved areas. The community pharmacy chain offers coaching, mentoring, and training programs through hundreds of partnerships with state and local programs across the country, says Ernie DuPont, senior director of workforce initiatives for CVS Health. "The pharmacy technician program not only benefits students by placing them in high demand, good-paying jobs, but it benefits Baltimore employers who need well trained, reliable employees," says James Johnson, interim president at Baltimore City Community College. Maryland has nearly 12,000 registered pharmacy technicians, and the number is growing, notes Deena Speights-Napata, executive director of the Maryland Board of Pharmacy. (Click for more...) 'We're passionate about it': Pharmacists help Coloradans quit smoking 10/12/2018 3:05:01 PM 'We're passionate about it': Pharmacists help Coloradans quit smoking Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Under a new law, pharmacists in Colorado can now prescribe medications to help people stop smoking. To qualify, they must have their doctorate or at least 5 years of experience and complete additional training. "Being able to provide an extra way for people to access what they need to help quit is amazing," said Emily Zadvorny, clinical associate professor for the CU Skaggs School of Pharmacy and the executive director of the Colorado Pharmacists Society. She said the pharmacy also allows for more flexibility because locations are open in the evenings and on weekends and holidays. "It really has the most impact in the rural communities where they don't necessarily have as many primary care providers that are available," said Dan Scales, a pharmacist and owner of Scales' Pharmacy in Denver. He added that people might be reluctant to go to their own doctor, but most patients have a good relationship with their pharmacy because they deal with them regularly. (Click for more...) Walgreens celebrates American Pharmacists Month by spotlighting expanding role 10/12/2018 3:05:01 PM Walgreens celebrates American Pharmacists Month by spotlighting expanding role Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 In observance of American Pharmacists Month in October, Walgreens is recognizing its more than 28,000 pharmacists for their commitment to care and their role in improving patient outcomes throughout the United States and Puerto Rico. Walgreens supports pharmacists by implementing personalized adherence tools, such as the Patient Care Portal that allows pharmacists to prioritize patients who have fallen behind on their medication schedule due to issues such as forgetfulness or adverse effects. Walgreens will also acknowledge its pharmacy technicians on National Pharmacy Technician Day (October 16), its physician assistants during National Physician Assistant Week (October 6-12), and its Healthcare Clinic nurse practitioners during National Nurse Practitioner Week (November 11–17). "As a pharmacist, I've seen first-hand how the role has evolved beyond filling prescriptions—and why it's more worthy than ever of our gratitude and respect," says Richard Ashworth, Walgreens president of operations. "Our pharmacists deliver a variety of health care services and are relied upon to provide trusted advice and support. For millions of Americans, their Walgreens pharmacist is an essential partner in ensuring their health and quality of life—and we thank them for rising to that everyday challenge." (Click for more...) How pharma packaging innovation is helping pharmacists boost medicine adherence 10/12/2018 3:05:01 PM How pharma packaging innovation is helping pharmacists boost medicine adherence Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Research shows that many patients who are prescribed medication do not comply with adherence advice. However, innovative medication packaging is making medication adherence simpler for patients and pharmacists. For example, "smart" blister packs utilize a built-in microchip to capture use-related data and remind patients when their next dose of medicine is due. Pharmacists can also access the data collected from these packs to see a patient's medicine-taking behavior at home. Although technology is useful, face-to-face conversations are essential in equipping patients with the knowledge to benefit from adherence devices. Additionally, since every individual has a different amount of digital knowledge, a pharmacist must approach each patient individually to consider what product will best help them. (Click for more...) Pfizer settles New York probe into 'deceptive' copay coupons 10/12/2018 3:05:01 PM Pfizer settles New York probe into 'deceptive' copay coupons Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Pfizer on Thursday settled charges by New York's attorney general that it misled consumers in its drug copayment coupon program into thinking they would pay far less to fill prescriptions than what they actually wound up paying. Pfizer agreed to pay $500,000 in fines and costs, and make more than $200,000 in restitution over the coupons. New York Attorney General Barbara Underwood said the drug manufacturer's coupons were "deceptive" because Pfizer buried limits on the total savings in the small print, and that thousands of consumers ended up paying much more. The settlement resolves claims from 2014 to 2017, and Underwood said the rate at which New York consumers paid more than the advertised maximums went up over time. Pfizer acknowledged some of the attorney general's findings but did not admit or deny liability. Reimbursements will go to consumers who used coupons in the last 3 years. (Click for more...) Top Democrats express concern on FDA's effort to relax regulations on digital health apps, other software 10/12/2018 3:05:01 PM Top Democrats express concern on FDA's effort to relax regulations on digital health apps, other software Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Democrats on the Senate health committee have expressed concern about how FDA plans to regulate medical software, including smartphone apps. FDA has been working with a number of companies over the past year to develop a program that would allow companies to sell some medical software without the agency reviewing it. Instead of approving specific products, FDA would "pre-certify" companies—based on criteria that has not yet been specified—and the companies would then be able to market certain software without requiring FDA review and other software with "streamlined" review, according to FDA Commissioner Scott Gottlieb in a September 2017 speech. In a new letter to the agency, Sens. Elizabeth Warren (D-MA), Patty Murray (D-WA), and Tina Smith (D-MN) wrote: "It is essential that changes to FDA's regulatory framework are done in compliance with the current statutory framework and do not compromise public safety." The senators expressed concern about how the process would work and how much information the companies will have to share with the public to qualify for pre-certification. (Click for more...) Walgreens's U.S. pharmacy sales climb 10/12/2018 3:05:01 PM Walgreens's U.S. pharmacy sales climb Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Walgreens Boots Alliance reports growth in prescription volumes helped increase pharmacy sales in its latest quarter, as the company's integration of Rite Aid stores expanded its foothold in the U.S. prescription market. Walgreens’s share of the U.S. retail prescription market this year has grown to a company record 21.7%, compared with 20.2% in 2017, Walgreens Chief Financial Officer James Kehoe said Thursday, citing data from health care research firm Iqvia. For the fourth quarter, Walgreens filled the largest number of prescriptions in its history, mainly due to its retention of many Rite Aid prescription drug customers after taking over those stores. U.S. pharmacy sales rose 17% from the year-earlier quarter while prescriptions filled in comparable stores increased 1.3%. Overall sales rose 11% to $33.44 billion. Growth in Walgreens's pharmacy business helped offset weakness in sales of general merchandise and personal care items. Comparable U.S. retail sales in the fourth quarter fell 1.9% from a year earlier. (Click for more...) Flu vaccine reduces risk of flu hospitalization among pregnant women 10/12/2018 3:05:01 PM Flu vaccine reduces risk of flu hospitalization among pregnant women Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Obtaining an influenza vaccination lowered a pregnant woman's risk of influenza-related hospitalization by about 40%, on average, researchers report. The information, derived from a multi-county, CDC-coauthored study, is published in Clinical Infectious Diseases. According to CDC, this is the first report to demonstrate that vaccination can protect pregnant women against hospitalization due to influenza. "Expecting mothers face a number of threats to their health and the health of their baby during pregnancy, and getting the flu is one of them," explains Allison Naleway, PhD, a study coauthor from the Kaiser Permanente Center for Health Research. "This study's findings underscore the fact that there is a simple, yet impactful way to reduce the possibility of complications from flu during pregnancy: get a flu shot." For the study, CDC teamed up with public health agencies and health care systems in the United States as well as Australia, Canada, and Israel through the Pregnancy Influenza Vaccine Effectiveness Network. The sites retrospectively assessed medical records for more than 2 million women who were pregnant from 2010 through 2016 to identify those who were hospitalized with lab-confirmed influenza. The study also noted that more than 80% of pregnancies overlapped with the influenza season, highlighting the likelihood that pregnant women will be exposed to influenza at some point during their pregnancy; the influenza vaccine was equally protective for women with underlying medical conditions; and it was equally protective for women during all three trimesters of pregnancy. (Click for more...) FDA releases method for detection and quantification of both NDMA and NDEA 10/12/2018 3:05:01 PM FDA releases method for detection and quantification of both NDMA and NDEA Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 FDA has redeveloped a testing method in order to detect the presence of the impurities N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) in valsartan drug products. A previously posted combined gas chromatography-mass spectrometry (GC/MS) method was used for the detection of NDMA in valsartan products; however, that method was reworked following detection of NDEA in valsartan products manufactured by Zhejiang Huahai Pharmaceuticals. FDA noted it is also working to develop a GC/MS direct injection method for detection of NDMA and NDEA, and will post that information when it is available. More information about the combined GC/MS headspace method for detecting NDMA and NDEA is available here. (Click for more...) Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy 10/12/2018 3:05:01 PM Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Researchers at Houston's M.D. Anderson Cancer Center report on the results of an experimental treatment administered to three immunocompromised patients with progressive multifocal leukoencephalopathy (PML). The fact that the JC virus underlying PML is genetically similar to the BK virus, which causes nephritis and cystitis in patients after stem cell transplantation, gave the team reason to believe that PML patients might respond to T cells designed to combat BK virus. In two patients, infusion of BK virus-specific T cells was followed by clearing of the JC virus from cerebrospinal fluid and alleviation of clinical symptoms and evidence of PML. JC viral load was reduced in the third patient, and her symptoms stabilized until she died—which was 8 months after the first infusion of BK T cells. The findings from this proof-of-principle study suggest that third-party–produced, "off-the-shelf," partially HLA-matched, BK virus–specific T cells may be a viable therapy for PML. Additional large-scale trials are warranted to determine the success rate, durability, and longer-term adverse events associated with this intervention. (Click for more...) Timing of renal-replacement therapy in patients with acute kidney injury and sepsis 10/12/2018 3:05:01 PM Timing of renal-replacement therapy in patients with acute kidney injury and sepsis Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 Severe acute kidney injury is an independent risk factor for death in the setting of septic shock, even after renal-replacement therapy to treat the damage. Researchers in France, however, wondered if whether time to initiation of dialysis plays a role in mortality. To investigate further, they conducted a multisite trial that included 477 patients in the final analysis. Participants were all in the "failure" stage of the RIFLE (risk, injury, failure, loss, and end-stage) kidney disease classification system and were in the early stages of septic shock. Each was randomly allocated to undergo renal-replacement therapy within 12 hours of acute kidney injury or after 48 hours in the absence of renal recovery. The primary endpoint was 90-day mortality, which occurred at a rate of 58% among the patients who received renal-replacement therapy early vs. 54% among the patients who received delayed treatment. The difference was not considered to be statistically significant, leading researchers to conclude that early dialysis does not improve mortality rates at 90 days vs. delayed dialysis. (Click for more...) Walgreens survey finds 70% of Americans planning to get vaccinated against influenza 10/12/2018 3:05:01 PM Walgreens survey finds 70% of Americans planning to get vaccinated against influenza Thu, 10/11/2018 - 20:00 cbaker_admin Fri, 10/12/2018 - 15:05 The results of a new survey from Walgreens indicate that 54% of Americans said they expect to get vaccinated against influenza earlier this year, and 70% plan to get vaccinated at some point this year. In all, 40% of the respondents said they expect this season to be about as severe as last year's, while 12% expect this year will be worse. Still, about a third of those surveyed said they had not been vaccinated against influenza in the past 3 years, with about 39% of those individuals saying they thought the vaccine was not effective. Additionally, about 37% of the respondents said they had gone to work while sick with influenza. (Click for more...) Atropine Sulfate Injection 10/11/2018 8:00:00 PM Drug: Atropine Sulfate Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Chloroprocaine Hydrochloride Injection 10/11/2018 8:00:00 PM Drug: Chloroprocaine Hydrochloride Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Diazepam Injection 10/11/2018 8:00:00 PM Drug: Diazepam Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Fentanyl Citrate Injection 10/11/2018 8:00:00 PM Drug: Fentanyl Citrate Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Heparin Sodium Premixed Bags 10/11/2018 8:00:00 PM Drug: Heparin Sodium Premixed Bags, Revision Date: Fri, 12 Oct 2018 (Click for more...) Iron Dextran Injection 10/11/2018 8:00:00 PM Drug: Iron Dextran Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Ketamine Injection 10/11/2018 8:00:00 PM Drug: Ketamine Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Meperidine Hydrochloride Injection 10/11/2018 8:00:00 PM Drug: Meperidine Hydrochloride Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Mycophenolate Mofetil Capsules and Tablets 10/11/2018 8:00:00 PM Drug: Mycophenolate Mofetil Capsules and Tablets, Revision Date: Fri, 12 Oct 2018 (Click for more...) Procainamide Hydrochloride Injection 10/11/2018 8:00:00 PM Drug: Procainamide Hydrochloride Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Progesterone Injection 10/11/2018 8:00:00 PM Drug: Progesterone Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Remifentanil Injection 10/11/2018 8:00:00 PM Drug: Remifentanil Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Sodium Bicarbonate Injection 10/11/2018 8:00:00 PM Drug: Sodium Bicarbonate Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Valsartan and Hydrochlorothiazide Tablets 10/11/2018 8:00:00 PM Drug: Valsartan and Hydrochlorothiazide Tablets, Revision Date: Fri, 12 Oct 2018 (Click for more...) Vecuronium Bromide Injection 10/11/2018 8:00:00 PM Drug: Vecuronium Bromide Injection, Revision Date: Fri, 12 Oct 2018 (Click for more...) Opioid-benzo overlap higher in patients using multiple health systems 10/11/2018 2:05:01 PM Opioid-benzo overlap higher in patients using multiple health systems Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 Researchers have found that patients with drug coverage through multiple health care systems are more likely to experience an overlap in opioid and benzodiazepine prescriptions. The danger of using these two types of drugs concomitantly is recognized and acknowledged in the medical community, but investigators say that having two or more providers creates an opportunity for simultaneous opioid and benzodiazepine prescriptions to slip through the cracks. The team from the VA Pittsburgh Healthcare System examined records for 368,891 beneficiaries of both VA and Medicare Part D programs who filled two or more opioid prescriptions within 15 days during 2013. The Department of Veterans Affairs (VA) alone filled the orders for 18.3% of the patients, and Medicare was the sole source for 30.3%. However, 51.4% received prescriptions from both plans. When that happened, the investigators reported in Annals of Internal Medicine, the risk of overlapping opioid and benzodiazepine prescriptions rose significantly. Researcher Walid Gellad, MD, MPH, noted, however, that the study was conducted before widespread implementation of prescription drug monitoring programs by states and "robust" use of the databases throughout the VA system. "It remains to be seen whether PDMPs can help limit these overlaps within VA," Gellad said. (Click for more...) Association between third-trimester Tdap immunization and neonatal pertussis antibody concentration 10/11/2018 2:05:01 PM Association between third-trimester Tdap immunization and neonatal pertussis antibody concentration Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 The results of a new single-center study indicate that tetanus, diphtheria, and acellular pertussis (Tdap) immunization during the third trimester of pregnancy was associated with higher neonatal concentrations of pertussis toxin antibodies when compared with no immunization. Concentrations were highest when Tdap immunization occurred at 27–30 weeks, researchers report. The prospective cohort study of 626 pregnancies in Houston found that neonates whose mothers received Tdap immunization during weeks 27–36 of pregnancy had a geometric mean concentration of pertussis toxin antibodies in their cord blood of 47.3 IU/mL, compared with 12.9 IU/mL for neonates whose mothers did not receive the Tdap vaccine during pregnancy. "This study is the first, to our knowledge, to evaluate a large cohort of newborn infants born at term to mothers who received Tdap vaccine in accordance with the current U.S. recommendations," the researchers conclude. "These serologic findings may help to explain why epidemiologic studies demonstrated reduction in infant pertussis following third-trimester immunization in the United States and in the United Kingdom, where pertussis booster vaccine was given during weeks 28 to 38 of pregnancy and resulted in a 91% reduction in pertussis in infants 3 months or younger." (Click for more...) Gene mutation points to new way to fight diabetes, obesity, heart disease 10/11/2018 2:05:01 PM Gene mutation points to new way to fight diabetes, obesity, heart disease Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 A study primarily supported by the National Heart, Lung, and Blood Institute indicates that people with a gene mutation that slows the metabolism of sugar in the gut might have a lower risk of diabetes, obesity, heart failure, and even death. Scott D. Solomon, MD, a professor of medicine at Harvard Medical School and a senior physician at Brigham and Women's Hospital in Boston, who led the research, says the study is the first to fully examine the link between mutations in the gene mainly responsible for absorbing glucose in the gut—SGLT-1, or sodium glucose co-transporter-1—and cardiometabolic disease. Researchers analyzed the relationship between SGLT-1 mutations and cardiometabolic disease using genetic data obtained from about 8,500 participants in the Atherosclerosis Risk in Communities study, a 25-year-long observational trial of atherosclerosis and cardiovascular risk factors in people living in four U.S. communities. The researchers found that about 6% of the subjects carried a mutation in SGLT-1 that causes limited impairment of glucose absorption, resulting in reduced incidence of type 2 diabetes, heart failure, and obesity. These individuals also had a lower mortality rate compared with those without the mutation, even after adjusting for dietary intake. The researchers warn that developing drugs to selectively block the SGLT-1 receptor could take years, and that clinical trials are still needed to determine if the drugs reduce the incidence of diabetes and heart failure and improve lifespan. (Click for more...) Walgreens and LabCorp to open at least 600 LabCorp at Walgreens patient service centers 10/11/2018 2:05:01 PM Walgreens and LabCorp to open at least 600 LabCorp at Walgreens patient service centers Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 Walgreens and LabCorp are significantly expanding their LabCorp at Walgreens partnership, saying they will open at least 600 LabCorp patient service centers at Walgreens locations during the next 4 years. Since the two companies first announced the consumer-focused initiative in June 2017, 17 LabCorp at Walgreens locations have opened in Florida, Colorado, North Carolina, and Illinois. The sites--which offer specimen collection services for LabCorp testing in a secure, comfortable setting--are located near the pharmacy area inside the Walgreens stores. "LabCorp's strong partnership on this joint initiative, coupled with the enthusiastic consumer feedback we've received, allows us to undertake an exciting expansion of our collaboration together," said Stefano Pessina, executive vice chairman and CEO of Walgreens Boots Alliance. "This reflects our commitment to transform our stores into neighborhood health destinations that provide a differentiated, consumer-focused experience, while providing access to a broad range of affordable health care services at a trusted and convenient setting." (Click for more...) Wegmans ranked highest in customer satisfaction among supermarket pharmacies 10/11/2018 2:05:01 PM Wegmans ranked highest in customer satisfaction among supermarket pharmacies Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 The recently released J.D. Power 2018 U.S. Pharmacy Study ranked Wegmans Pharmacy highest in customer satisfaction among supermarket pharmacies. The study, now in its tenth year, measures customer satisfaction among all categories of "brick and mortar" pharmacies, including community pharmacy chains, mass merchants, and supermarkets. Wegmans received the highest score in four of the five factors measured: prescription ordering and filling process, store, non-pharmacist staff, and cost competitiveness. The 2018 study is based on responses from 10,749 pharmacy customers who filled a prescription during the 3 months prior to the survey period of May-June 2018. Of the different pharmacy segments, supermarkets have the highest levels of overall satisfaction. (Click for more...) CVS completes rollout of time-delay safes in California stores 10/11/2018 2:05:01 PM CVS completes rollout of time-delay safes in California stores Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 CVS Pharmacy's rollout of time-delay safes in almost 900 of its free-standing stores in California is complete, the company said Wednesday. The safes aim to prevent pharmacy robberies and combat the opioid crisis by preventing diversion of controlled substances. "Pharmacy robberies are a challenging issue for every pharmacy, and we are committed to doing all we can to reduce the number of pharmacy robbery incidents in our California stores," said Hank Casillas, division vice president of CVS Pharmacy in California. "We have seen that time-delay safes, combined with the other security policies and procedures in place at our stores, can greatly reduce these incidents and are pleased to roll out this enhanced security measure. These safes will help ensure that our stores remain a safe environment for our patients and colleagues." All CVS locations with the new safes—whose time-delay function cannot be overridden—will feature highly visible signage to let the public know that time-delay safes are in use there to prevent on-demand access to controlled substances. CVS Health has also finished installing more than five dozen safe medication disposal units in CVS Pharmacy locations in California, adding to the 21 units it has donated to law enforcement agencies in the state. (Click for more...) Walmart joins CVS, Kroger in preferred pharmacy network for ESRX Saver plan 10/11/2018 2:05:01 PM Walmart joins CVS, Kroger in preferred pharmacy network for ESRX Saver plan Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 Express Scripts has introduced its Express Scripts Medicare Prescription Drug Plan (PDP) offerings for 2019. The company reports that its low-premium Saver plan, which made its debut in 2018, will continue to provide affordable access to more than 2,800 commonly used medications while offering an expanded preferred pharmacy network that will now include Walmart in addition to CVS Pharmacy and the Kroger Family of Pharmacies. The Saver plan offers a premium as low as $23.90 per month and a $0 deductible on Tier 1 and Tier 2 generics. Copays are $1 for a one-month supply of Tier 1 generic medications and $4 for Tier 2 generic medications when filled at one of the preferred community pharmacies nationwide. The Express Scripts Medicare Value and Choice plans provide broader medication access and preferred pharmacy options. The Choice plan also provides coverage in the Gap for a select group of Tier 3 brand drugs above the standard Gap coverage. Enrollment for the 2019 plan year runs from October 15 through December 7. Coverage begins on January 1, 2019. (Click for more...) 3 tips to get your pharmacy ready for cold and influenza season 10/11/2018 2:05:01 PM 3 tips to get your pharmacy ready for cold and influenza season Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 There are three main ways that pharmacies, specifically those located within retail locations, can build loyalty with shoppers during the cold and influenza season. First, in-store pharmacies should utilize the entire store and encourage customers to speak to the pharmacist. For example, cashiers at a grocery store should remind shoppers that the pharmacy provides the influenza vaccine. Second, pharmacists should step out from behind the counter and into the aisles. When shoppers see a pharmacist out in the store, such as by the OTC medicines, they feel more comfortable asking questions. This allows pharmacists to engage shoppers and provide guidance on overall care. Lastly, pharmacists should practice good customer service skills by helping patients find everything they need and directing customers to other locations in the store where they can purchase supplemental items that will support them in their recovery. Using these tips during cold and influenza season will encourage customers to visit the in-store pharmacy for ongoing care. (Click for more...) This brand-new advocacy group is an unapologetic defender of high drug prices 10/11/2018 2:05:01 PM This brand-new advocacy group is an unapologetic defender of high drug prices Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 The Alliance to Protect Medical Innovation, a new pharma advocacy group, is defending expensive list prices for prescription drugs. The group says its goal is to "help educate policymakers and the public about medical breakthroughs developed by the biopharmaceutical industry." An "About Us" section on its website describes it as a 501(c)(4) nonprofit. It is uncertain who funds the group or who is running its day-to-day operations. The group's website warns that insurers and PBMs are pushing "short-sighted policies that would disrupt the development of the cures and medicines that patients depend on." Ben Wakana, the executive director of Patients for Affordable Drugs, said in a statement the group "should disclose its funders immediately." (Click for more...) CVS Health and Aetna $69 billion merger is approved with conditions 10/11/2018 2:05:01 PM CVS Health and Aetna $69 billion merger is approved with conditions Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 Pharmacy chain CVS Health won U.S. antitrust approval for its $69 billion acquisition of health insurer Aetna, the Justice Department said on Wednesday, paving the way for a combination with potential to cut U.S. health care costs for consumers. The merger approval caps a wave of consolidation among large health care companies that some say could leave U.S. consumers with less control over their medical care and prescription drugs. As the last major free-standing pharmacy manager, CVS Health had revenues of about $185 billion last year, and provided prescription plans to approximately 94 million customers. Aetna covers 22 million people in its health plans. The two companies say that they will be better able to coordinate care for consumers as the mergers help tighten cost controls. Larry J. Merlo, the CEO of CVS Health, said in a statement that the approval "is an important step toward bringing together the strengths and capabilities of our two companies to improve the consumer health care experience." State regulators and consumer groups have raised concerns about the effect of the merger, saying that the lack of large pharmacy managers that are not affiliated with insurers could make it difficult for smaller competitors in either sector. (Click for more...) Trump signs new laws aimed at drug costs 10/11/2018 2:05:01 PM Trump signs new laws aimed at drug costs Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 President Trump signed into law legislation on Wednesday that frees pharmacists to tell consumers when they can actually save money by paying the full cash price for prescription drugs rather than using health insurance with large co-payments, deductibles, and other out-of-pocket costs. Pharmacists around the country say they have often been forbidden to share information on drug pricing with customers. The new law will "completely end these unjust gag clauses once and for all," Trump said. He signed two bills. One bill, introduced by Sen. Susan Collins (R-ME), bans gag clauses in commercial health insurance, including coverage offered by employers and plans bought by individuals and families on their own. The other bill, introduced by Sen. Debbie Stabenow (D-MI), applies to outpatient drug coverage in Medicare, whether provided by the traditional fee-for-service program or by private Medicare Advantage plans. "Insurance is intended to save consumers money," Collins said. "Gag clauses do the opposite. They prevent pharmacists from telling patients how to pay the lowest possible price for their prescription drugs." Steven F. Moore, whose family owns Condo Pharmacy in Plattsburgh, NY, said the new federal laws would be "a big help." The restrictions on pharmacists' ability to discuss prices with patients are "incredibly frustrating," he said. (Click for more...) Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level 10/11/2018 2:05:01 PM Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level Wed, 10/10/2018 - 20:00 cbaker_admin Thu, 10/11/2018 - 14:05 In patients with septic shock and high levels of endotoxin in the blood, researchers wondered if adding polymyxin B hemoperfusion to standard treatment would not only dial back the endotoxin activity but also improve clinical outcomes. They assembled a study population of 450 critically ill adults in the United States and Canada who fit the patient profile, randomizing them to usual care plus sham or real polymyxin B hemoperfusion. The main endpoint was 28-day mortality, which was 34.5% with sham hemoperfusion and 37.7% with polymyxin B hemoperfusion. Based on the trial results, the investigators concluded that polymyxin B hemoperfusion did not prolong survival in patients with septic shock and high levels of endotoxin in the blood. (Click for more...) Rapid Growth and Promising Partnerships 10/11/2018 11:38:59 AM Beacon Discovery is a science-focused company with a huge breadth of experience in discovering and developing drugs that target G-Protein Coupled Receptors (GPCRs) – and, in the two years since our founding in September 2016, we have already achieved some important milestones. Specifically, we have announced three major drug discovery collaborations: two with large pharmaceutical […] (Click for more...) Asparaginase Erwinia chrysanthemi 10/10/2018 8:00:00 PM Drug: Asparaginase Erwinia chrysanthemi, Revision Date: Thu, 11 Oct 2018 (Click for more...) Enoxaparin Sodium Injection 10/10/2018 8:00:00 PM Drug: Enoxaparin Sodium Injection, Revision Date: Thu, 11 Oct 2018 (Click for more...) Ketorolac Injection 10/10/2018 8:00:00 PM Drug: Ketorolac Injection, Revision Date: Thu, 11 Oct 2018 (Click for more...) President’s signature frees pharmacists to help patients identify ways to decrease their medication costs 10/10/2018 4:22:26 PM President’s signature frees pharmacists to help patients identify ways to decrease their medication costs Wed, 10/10/2018 - 16:29 caldridgeyoung… Wed, 10/10/2018 - 16:22 President Trump has signed into law two popular bills striking down so-called “gag clauses” in PBM contracts. Gag clauses barred pharmacists from telling patients the cash price of their medications, even when the out-of-pocket cost was lower than their copay. With the new laws, PBMs can no longer penalize pharmacists who share cost information with patients. (Click for more...) No more secrets: Congress bans pharmacist 'gag orders' on drug prices 10/10/2018 1:05:01 PM No more secrets: Congress bans pharmacist 'gag orders' on drug prices Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 President Donald Trump is expected to sign two bills Wednesday that ban "gag order" clauses in contracts between pharmacies and insurance companies or PBMs. Ronna Hauser, vice president of payment policy and regulatory affairs at the National Community Pharmacists Association, says many members of her group "say a PBM will call them with a warning if they are telling patients it’s less expensive" without insurance. She says pharmacists could be fined for violating their contracts and even dropped from insurance networks. After the president signs the legislation affecting commercial insurance contracts, gag order provisions will immediately be prohibited, according to a spokesman for Sen. Susan Collins (R-ME), who coauthored the bill. The bill affecting Medicare beneficiaries will not take effect until January 1, 2020. Under the new legislation, pharmacists will not be required to tell patients about the lower cost option. If they do not, it is up to the customer to ask. Rep. Buddy Carter (R-GA), a pharmacist who sponsored the Medicare gag order bill, says he is not surprised by the bipartisan support for the legislation. "High prescription drug costs affect everyone," he notes. (Click for more...) Long term adjuvant endocrine therapy and risk of CVD in female breast cancer survivors 10/10/2018 1:05:01 PM Long term adjuvant endocrine therapy and risk of CVD in female breast cancer survivors Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 U.K. researchers examined whether taking tamoxifen or aromatase inhibitors influenced cardiovascular disease (CVD) outcomes in women with a history of non-metastatic breast cancer. The investigation took the shape of a systematic review and meta-analysis, with evidence from 26 relevant studies published up to June 2018. The findings suggested an association between tamoxifen, vs. aromatase inhibitors or no endocrine therapy, and venous thromboembolism. Aromatase inhibitor use, meanwhile, was correlated with myocardial infarction and angina—although that might be attributed in part to tamoxifen's protective effect on those two outcomes. The data was limited and inconsistent for the remaining CVD endpoints, including stroke, heart failure, arrhythmia, and peripheral vascular disease. The review authors conclude that patient risk of venous or arterial vascular disease should help inform choice of tamoxifen or aromatase inhibitor, although effectiveness against breast cancer recurrence will serve as primary deciding factor. (Click for more...) NSAID use among patients with a musculoskeletal disorder and hypertension, heart failure, or CKD 10/10/2018 1:05:01 PM NSAID use among patients with a musculoskeletal disorder and hypertension, heart failure, or CKD Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 A retrospective cohort study conducted in Toronto sought to characterize the frequency and associations of prescription NSAID use among patients with high blood pressure, heart failure, or chronic kidney disease (CKD). Researchers were also interested to see if NSAID use correlated with short-term safety outcomes. The cohort included more than 814,000 individuals aged 65 years or older with a history of one of the three targeted conditions. Patients attended more than 2.4 million musculoskeletal-related primary care visits during the study period, and 9.3% of those sessions were followed by prescription NSAID use within the course of 1 week. Cardiovascular and renal safety outcomes were assessed for 8–37 days after each visit, but there was no difference based on comparisons of patients exposed to prescription NSAIDs and nonexposed patients. The researchers did discover that past NSAID users, patients with hypertension, and younger people were more likely to use prescription NSAIDs, while those with CKD, heart failure, previous opioid use, and hospitalization within the past year were less likely. In general, moreover, prescription NSAID users tended to be healthier and have less severe disease than nonusers. (Click for more...) FDA approves Akcea rare disease drug with a black box warning 10/10/2018 1:05:01 PM FDA approves Akcea rare disease drug with a black box warning Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 FDA has approved inotersen (Tegsedi—Akcea Therapeutics) with a black box warning. The drug is indicated to treat the nerve pain, not heart damage, associated with the rare and fatal condition hereditary transthyretin amyloidosis (hATTR). The approval is a win for Akcea after FDA declined to approve another one of the company’s drugs based on the same technology. Inotersen is the second drug on the U.S. market for hATTR. In August, patisiran sodium (Onpattro—Alnylam) received FDA approval for hATTR. Patisiran sodium requires an I.V. infusion every 3 weeks, while patients can inject themselves with inotersen once a week. However, FDA requires patients using inotersen to have platelet monitoring at least weekly, as well as biweekly kidney tests and liver tests to be done 3 times a year. The drug has been available in Europe since July and was approved in Canada just last week. Akcea is ready to launch in the U.S. immediately, according to company CEO Paula Soteropoulos. "We have a full sales team that’s been on the ground already connecting with the physicians, helping to find the patients, nursing case management team is on the ground, and market access team is working with payers," she added. (Click for more...) FDA posts laboratory analysis of NDMA levels in recalled valsartan products 10/10/2018 1:05:01 PM FDA posts laboratory analysis of NDMA levels in recalled valsartan products Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 As part of its ongoing investigation into the presence of impurities in valsartan products, FDA has released lab test results with NDMA levels in the recalled products. In addition, the agency will release the test results and an analysis of the cancer risk from NDEA when they are available. (Click for more...) Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events 10/10/2018 1:05:01 PM Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 Researchers wanted to understand how high levels of lipoprotein(a), a known genetic risk factor for cardiovascular disease (CVD), affect patients with established disease—particularly those taking statins. They conducted a meta-analysis of individual patient data from seven randomized, controlled trials that investigated outcomes with statin therapy. Based on information from more than 29,000 study participants, the team determined that starting on statins reduced LDL cholesterol without much of an effect on lipoprotein(a). Levels of lipoprotein(a) at baseline and on statins were roughly linear with CVD risk, with risk increasing at thresholds of 30 mg/dL or higher and 50 mg/dL or higher, respectively. The findings offer a rationale for testing the lipoprotein(a)-lowering hypothesis in studies with CVD endpoints, the review authors conclude. (Click for more...) Immune checkpoint inhibitor toxicity in 2018 10/10/2018 1:05:01 PM Immune checkpoint inhibitor toxicity in 2018 Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 With physicians prescribing more immune checkpoint inhibitors (ICIs) to combat cancer, understanding the adverse events (AEs) associated with these antibodies takes on increasing importance. Immunologic toxicity is common with ICIs, which act by blocking cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death 1, or programmed death ligand 1. AEs usually surface during the first 3 months of therapy, but they can also present 6 months after treatment has ended. Immediate initiation of 1–7 days of steroid treatment resolves most AEs, but they can return and even require hospitalization. Patients who do not respond within 3–7 days of steroid initiation are candidates for disease-specific, second-line immunosuppression. Of particular concern are autoimmune AEs, which can compromise the patient's organs. This type of AE is more dramatic with anti-CTLA-4 therapies and occurs both earlier and more often than with programmed death monotherapy. Low-dose glucocorticoids typically treat mild cases, with high-dose glucocorticoids used for more severe cases. Rigorous studies must be performed to gain better insight into the pathophysiology of ICI-associated AEs, to flag high-risk patients, and to develop evidence-based therapies to manage toxicity. (Click for more...) Walgreens mobilizes in advance of Hurricane Michael 10/10/2018 1:05:01 PM Walgreens mobilizes in advance of Hurricane Michael Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 As Hurricane Michael moves closer, Walgreens is taking proactive steps to help its customers, employees, and communities in the hurricane's project path. These measures include prescription drug preparedness, customers support, and relief and recovery. With a state of emergency declared in parts of Florida, pharmacists in the state can refill medications up to a 30-day supply without requiring a prescriber's refill authorization for any non-controlled substance. Walgreens also recommends that patients carry with them any current medications in a waterproof bag, even if the bottle is empty, as the prescription label information will be useful for refill requests. "We urge our patients and customers to follow state of emergency directives and if necessary get to a safe location first and then refill medications at the nearest pharmacy. Walgreens will continue to support the health and wellness needs of our customers and communities facing this dangerous storm," said Richard Ashworth, Walgreens president of operations. "We have a dedicated team in our Emergency Operations Center working to ensure our team members in the storm's path remain safe and are preparing to rapidly restore operations in order to best serve our patients and communities." (Click for more...) Tackling fraud, waste and abuse in pharmacy care 10/10/2018 1:05:01 PM Tackling fraud, waste and abuse in pharmacy care Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 PBMs can play a key role in identifying and limiting fraud, waste, and abuse by conducting real-time audits of pharmacies' prescription claims, writes Heidi Lew, PharmD, vice president of Pharmacy Network Audit at OptumRx. These tools can help save employers and health plans hundreds of millions of dollars each year, and also guarantee medication health and safety for members. Real-time audits allow PBMs to correct claims or spot errors before clients are charged and before the drug is dispensed. Using new data analytics capabilities, PBMs can preemptively detect outlier activity in billing patterns and flag them for review. Examples of potentially fraudulent behaviors include increased billing volumes month over month, rising claims activity for select medications, and activity in HHS-OIG defined fraud strike force locations. As a pharmacy care services company that conducts these investigative audits, OptumRx can score and rank the more than 1.3 billion claims it processes each year in just seconds, flagging those with the highest risk, according to Lew. (Click for more...) ASHP publishes guidelines on preventing medication errors 10/10/2018 1:05:01 PM ASHP publishes guidelines on preventing medication errors Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 The American Society of Health-System Pharmacists (ASHP) has issued guidelines that offer best practices and recommendations for avoiding medication errors. The ASHP Guidelines on Preventing Medication Errors in Hospitals highlight the important leadership roles that pharmacists play and opportunities for them on interprofessional teams to limit errors. The guidelines urge organizations to have a comprehensive program that includes a medication safety head, an event reporting system, a collaborative medication safety team, and a continuous quality improvement philosophy about evaluation of errors and harm. "Pharmacists are the leaders in interprofessional efforts to prevent patient harm associated with medication errors," said ASHP chief operating officer and senior vice president Kasey K. Thompson, PharmD, MS, MBA. "These guidelines will serve as an exceptional resource for the entire patient-care team and reflect ASHP's 76-year commitment to constantly improving medication safety through the development of cutting-edge guidelines and other resources." The guidelines address numerous areas in the medication-use process where errors may occur, ranging from patient admission to storage and transcribing. (Click for more...) FDA efforts to advance the development of generic copies of complex drugs to improve patient access to medicines 10/10/2018 1:05:01 PM FDA efforts to advance the development of generic copies of complex drugs to improve patient access to medicines Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 FDA announced on Tuesday a series of guidance documents to further the development of generic transdermal and topical delivery systems (TDS). According FDA Commissioner Scott Gottlieb, "The increased transparency and predictability provided by these and other product-specific recommendations gives applicants seeking to develop generic copies of these complex products a better opportunity to efficiently advance these products and prepare better and more complete submissions." The guidances include the revised draft guidance, Assessing Adhesion with Transdermal and Topical Delivery Systems for ANDAs, and a second draft guidance, Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs. FDA is also releasing 25 product-specific guidance documents, including 2 new and 23 revised guidances, to support industry in identifying appropriate science-based methodologies and evidence for developing generic TDS products. Going forward, FDA plans to further other new policies to promote more generic competition for these complex drugs, Gottlieb said, and the agency will issue an umbrella guidance to help generic drug developers address some of the most challenging regulatory and scientific issues encountered when they try to make generic copies of complex drugs. Gottlieb noted, "Addressing these challenges—and promoting more generic competition to complex medicines—is a key part of our Drug Competition Action Plan, and our efforts to promote patient access and more affordable medicines." (Click for more...) FDA staff raises safety issues over Trevena opioid injection 10/10/2018 1:05:01 PM FDA staff raises safety issues over Trevena opioid injection Tue, 10/09/2018 - 20:00 cbaker_admin Wed, 10/10/2018 - 13:05 FDA staff reviewers on Tuesday warned that Trevena Inc.'s opioid injection to treat acute pain could be abused and potentially lead to overdose. The treatment, oliceridine, aims to manage moderate-to-severe acute pain in adult patients for whom an I.V. opioid is necessary. The injection should be administered in hospitals and ambulatory surgery centers. An FDA expert panel is expected to vote on the efficacy and safety of the treatment on Thursday. While FDA is not obliged to follow the panel's advice, it generally does so. (Click for more...) NIH awards WVU $11.2 million for interdisciplinary cancer research 10/10/2018 12:00:00 AM West Virginia University's School of Pharmacy will soon become one of the few pharmacy schools in the nation that leads a center of biomedical research excellence. Funded by the National Institutes of Health, these centers support interdisciplinary, thematically related research into preventing, diagnosing and treating health problems. (Click for more...) Cisplatin Injection 10/9/2018 8:00:00 PM Drug: Cisplatin Injection, Revision Date: Wed, 10 Oct 2018 (Click for more...) Early in the third trimester may be best for Tdap vaccination during pregnancy 10/9/2018 1:20:20 PM Early in the third trimester may be best for Tdap vaccination during pregnancy Tue, 10/09/2018 - 13:26 caldridgeyoung… Tue, 10/09/2018 - 13:20 When immunizing pregnant women with Tdap vaccine, timing matters, according to research published online in JAMA October 9. (Click for more...) FDA approves expanded use of HPV 9-valent vaccine recombinant to include individuals aged 27-45 years 10/9/2018 12:05:01 PM FDA approves expanded use of HPV 9-valent vaccine recombinant to include individuals aged 27-45 years Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 FDA has approved a supplemental application for the human papillomavirus 9-valent vaccine, recombinant (Gardasil 9—Merck, Sharp & Dohme Corp.) to widen the approved use of the vaccine to include women and men aged 27–45 years. "Today's approval represents an important opportunity to help prevent HPV-related diseases and cancers in a broader age range," said Peter Marks, MD, PhD, director of FDA's Center for Biologics Evaluation and Research. "CDC has stated that HPV vaccination prior to becoming infected with the HPV types covered by the vaccine has the potential to prevent more than 90% of these cancers, or 31,200 cases every year, from ever developing." FDA approved Gardasil 9, which protects against nine HPV types, in 2014 for use in males and females aged 9–26 years. The safety of Gardasil 9 was evaluated in about 13,000 individuals, and the most frequently reported adverse reactions were injection site pain, swelling, redness, and headaches. According to FDA, a study of about 3,200 women aged 27–45 years followed for an average of 3.5 years, found that Gardasil—which was approved in 2006 to prevent certain cancers and diseases caused by four HPV types and is no longer distributed in the U.S—was 88% effective in the prevention of a combined endpoint of persistent infection, genital warts, vulvar and vaginal precancerous lesions, cervical precancerous lesions, and cervical cancer related to HPV types covered by the vaccine. FDA's approval of Gardasil 9 in women aged 27–45 years of age is based on these results and new data on long-term followup from this study. The agency noted that Gardasil 9's efficacy in men aged 27–45 years "is inferred from the data described above in women 27–45 years of age, as well as efficacy data from Gardasil in younger men (16–26 years of age) and immunogenicity data from a clinical trial in which 150 men, 27–45 years of age, received a 3-dose regimen of Gardasil over 6 months." (Click for more...) Association of CKD with allopurinol use in gout treatment 10/9/2018 12:05:01 PM Association of CKD with allopurinol use in gout treatment Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 A research team from the State University of Rio de Janeiro in Brazil and the Boston University School of Medicine in Boston investigated the association of allopurinol use in gout with the risk of developing chronic kidney disease (CKD) stage 3 or higher. CKD stage 3 or higher occurs in 20% of patients with gout compared with 5% of those without gout, research shows. The time-stratified propensity score–matched, population-based, prospective cohort study included 4,760 individuals with newly diagnosed gout who initiated allopurinol (300 mg or more per day) and the same number of noninitiators of allopurinol. In all, 579 of the allopurinol initiators developed CKD stage 3 or higher, compared with 623 noninitiators. According to the researchers, use of allopurinol of 300 mg/day or more was linked to a lower risk of developing CKD stage 3 or higher when compared with nonusers. In addition, use of allopurinol at less than 300 mg/d was not associated with renal function decline. "Because allopurinol did not appear to be associated with renal function decline," the authors write, "clinicians should consider evaluating other factors when faced with renal function decline in their patients with gout rather than lowering the dose of or discontinuing allopurinol, a strategy that has contributed to the ongoing suboptimal treatment of gout." (Click for more...) Influenza can be a killer, but some refuse to get vaccinated 10/9/2018 12:05:01 PM Influenza can be a killer, but some refuse to get vaccinated Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 An estimated 80,000 Americans died after bouts of influenza during the 2017–18 season, CDC reports, compared with anywhere from 12,000–56,000 deaths during previous cycles. The most effective way to avoid becoming part of those statistics is to get vaccinated, yet fewer than one-half of the country's residents do so. According to a Rand Corp. survey, many adults believe immunization against influenza is unnecessary for them. Some assume their general good health will do enough to protect them, while others worry about getting sick from the vaccine itself—although the science demonstrates otherwise. Influenza vaccine is made from inactivated virus, not live virus; therefore, CDC says, getting influenza from the vaccine is impossible. Skeptics should consider CDC statistics showing that about 80% of children who die from influenza are not vaccinated. Giving an infected child the vaccine, however, can lower his or her mortality risk by 65%. (Click for more...) Six Minnesota kids suffer rare, polio-like disorder 10/9/2018 12:05:01 PM Six Minnesota kids suffer rare, polio-like disorder Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 Six Minnesota children have been diagnosed with acute flaccid myelitis (AFM) since September 20, causing state health officials to issue an alert to doctors. The disorder is rare, affecting less than 1 in 1 million children, and causes reduced mobility or paralysis in the limbs. Treatment and therapy can restore lost mobility in some children, but AFM can be fatal in individuals who lose the muscular function to breathe. "It is very rare and it is certainly something we're taking very seriously," said Kris Ehresmann, who directs the Minnesota Department of Health's infectious disease section. "It's a very devastating situation," she added. AFM came to the attention of CDC in 2014 after clusters of cases surfaced in Colorado and California. States have since reported 362 cases. Ehresmann hopes that closer examination of the children could reveal causes, but the cases are not even verified by lab test results. Ehresmann said it is the "constellation of symptoms" that connects them. "We're looking into any kind of commonality, but at this point … we don't have anything to wrap up in a bow," she said. Along with viruses, health officials believe the disorder is tied to unknown genetic and environmental factors. (Click for more...) FDA allows marketing of first self-fitting hearing aid controlled by the user 10/9/2018 12:05:01 PM FDA allows marketing of first self-fitting hearing aid controlled by the user Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 FDA on October 5 authorized marketing of the first hearing aid that enables users to fit, program, and control the device on their own. The Bose Hearing Aid (Bose Corp.) is intended to amplify sounds for individuals aged 18 years or older with perceived mild to moderate hearing loss. According to Malvina Eydelman, MD, director of the Division of Ophthalmic, and Ear, Nose and Throat Devices at FDA's Center for Devices and Radiological Health, "Today's marketing authorization provides certain patients with access to a new hearing aid that provides them with direct control over the fit and functionality of the device. The FDA is committed to ensuring that individuals with hearing loss have options for taking an active role in their health care." The Bose hearing aid must still comply with relevant federal and state laws regarding the sale of hearing aids, such as state laws that may require the devices to be purchased from or dispensed by a licensed hearing aid dispenser. FDA is now drafting proposed regulations for a category of OTC hearing aids as required by the FDA Reauthorization Act of 2017. (Click for more...) The uphill fight against fake prescription drugs 10/9/2018 12:05:01 PM The uphill fight against fake prescription drugs Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 The issue of counterfeit prescription medicine is a growing problem, attracting the attention of law enforcement organizations and pharmaceutical companies. FDA in June convened a meeting around the problem of illegal opioids sold online and through social media. In a survey conducted last year by the Alliance for Safe Online Pharmacies (ASOP Global), 55% of U.S. consumers said they have or would consider purchasing medicine online, notes Libby Baney, a senior adviser to the nonprofit. "The biggest danger is that these sites do not require a medical examination or a prescription, and the sites do not impose limitations on how much or how often the consumer purchases drugs," says Alex Khu, assistant director of the U.S. Immigration and Customs Enforcement's Global Trade Investigations division. The National Association of Boards of Pharmacy (NABP) reviewed nearly 12,000 internet outlets selling medicine to U.S. patients. Of these, about 95% were found noncompliant with state and federal laws and NABP standards, according to a report published in September, which highlighted the role social media sites play. The ASOP Global survey also found that more than 80% of doctors do not talk to patients about where they get their medicine. If a patient tells her doctor her medication is not working, a doctor unaware that she bought the product from a questionable source could mistakenly prescribe a higher dose or different product. (Click for more...) DEA joins HHS, ONDCP for listening session with nationwide drug prescribers 10/9/2018 12:05:01 PM DEA joins HHS, ONDCP for listening session with nationwide drug prescribers Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 DEA hosted on October 4 a listening session with HHS and Office of National Drug Control Policy officials to hear concerns from groups that represent drug prescribers nationwide as well as develop positive solutions to the issues these providers are confronted with. "DEA views the nearly 1.8 million registrants across the country as our partners and it is our duty and obligation to ensure their voices are heard," said John J. Martin, DEA Deputy Administrator who heads the Office of Diversion Control Division. "Part of DEA's regulatory and enforcement responsibilities must include productive, ongoing dialogue with these provider groups. These efforts improve our transparency, increase communication and help law enforcement understand the many challenges these providers face." Participants in the listening session include APhA, the American Medical Association, and the Federation of State Medical Boards. The meeting was part of DEA's outreach efforts to health care providers, registrants, pharmacy groups, and others who have worked with law enforcement to address key issues such as the nationwide opioid crisis. (Click for more...) Ohio taxpayers may be paying twice for the same Medicaid drug services 10/9/2018 12:05:01 PM Ohio taxpayers may be paying twice for the same Medicaid drug services Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 A team headed by Gary Rutherford, CEO of HealthPlan Data Solutions, that discovered Ohio taxpayers were overcharged up to $186 million for Medicaid prescription drugs last year has uncovered an additional $20 million that might have been wasted to fund services for which taxpayers already were paying. The team determined that PBMs were taking $149 million to $186 million a year above the industry's standard profit margin. Then Rutherford's auditors probed why Buckeye Community Health Plan—one of five managed-care organizations hired by the state to deliver health-care services to the 3 million Ohio residents on Medicaid—was charging the state more than twice the per-prescription costs of the other four. Buckeye charged an average of $11.60 each to fill the 4.6 million prescriptions it handled, compared with approximately $5.60 for the other four. Buckeye rolled up additional costs because it hired a company called Envolve to act as a pharmacy benefits "administrator"—even though Buckeye had hired CVS Caremark as a PBM. Envolve and Buckeye are both owned by the health care firm Centene. None of the four other managed care organizations saw a need to hire another company in addition to their PBM. (Click for more...) Seattle database tracks superbugs, helps hospitals find best drugs to fight them 10/9/2018 12:05:01 PM Seattle database tracks superbugs, helps hospitals find best drugs to fight them Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 A group called the Antibiotic Resistance Monitoring, Analysis & Diagnostics Alliance (ARMADA) says it wants to combat antibiotic resistance by building a database that tracks and "fingerprints" bacterial strains. ARMADA comprises physicians and scientists in Seattle who launched their nonprofit organization in September. Organization founder Evgeni Sokurenko, MD, PhD, observes: "How a patient will react to an infection will be tracked in their medical records, but nothing is being tracked about the bug, even though the bug will repeat itself, and no one will know what it has done in other patients." The group will collect data on how antibiotic-resistant bacteria react to multiple antibiotics. By furnishing this data to hospitals and microbiology labs, health practitioners would be immediately able to find the most effective drug for patients. The group has already gathered data for 30,000 strains and hopes to increase this number significantly in the next few years. The project receives funding from NIH and partners with Seattle Children's Hospital, Seattle-based Harborview Medical Center, and Oakland, CA-based Kaiser Permanente. (Click for more...) Makers of overdose antidote visit Pittsburgh to raise awareness about drug 10/9/2018 12:05:01 PM Makers of overdose antidote visit Pittsburgh to raise awareness about drug Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 To raise awareness about naloxone in Pennsylvania, Adapt Pharma has started a campaign featuring local doctors. According to DEA, almost 5,500 Pennsylvanians died from drug overdoses last year. Adapt Pharma, which is based in Pennsylvania, has launched TV ads in Pittsburgh and seven other selected areas, targeting prescription opioids and informing people about the availability of naloxone in local pharmacies, according to Thom Duddy, the company's vice president of corporate communications. A standing order issued by state Physician General Rachel Levine allows Pennsylvania pharmacies to distribute naloxone to anyone without a prescription. Duddy said Adapt Pharma chose to target Pittsburgh and the other areas because naloxone is available and affordable, local pharmacies stock the drug, and the cities have problems with opioid overdoses. Duddy noted that the company launched the awareness campaign because after talking to parents and spouses, they realized they "were completely unaware that there was a product like this that they could get and have in their home and give them peace of mind." (Click for more...) Congress targets misuse of hospice drugs 10/9/2018 12:05:01 PM Congress targets misuse of hospice drugs Mon, 10/08/2018 - 20:00 cbaker_admin Tue, 10/09/2018 - 12:05 A little-noticed provision of the opioids legislation headed to President Donald Trump's desk for his expected signature would allow hospice workers to destroy patients' unneeded opioids, reducing the risk that families misuse them. The bill would give hospice staff authority to destroy opioid medications that are expired, no longer needed by the patient because of a change in treatment, or leftover after the patient dies. Under current law, hospices cannot directly destroy patients’ unneeded opioid medications in the home. Instead, they direct families to mix them with kitty litter or coffee grounds before throwing them in the trash. The National Hospice and Palliative Care Organization applauded the proposed change in policy. "Granting appropriate hospice professionals the legal authority to dispose of unused medication after a hospice patient’s death would not only alleviate grieving families of this responsibility but also help prevent potential diversion or illicit use of these drugs," the group said in a statement. The legislation requires hospices to document policies on the disposal of opioid medications, and to discuss those policies with families. It also calls for the Government Accountability Office to study hospices' disposal of controlled substances in patients’ homes. (Click for more...) A run at regional office (Online Exclusive) 10/9/2018 11:09:31 AM A run at regional office (Online Exclusive) Wed, 10/10/2018 - 12:00 tenglish@aphanet.org Tue, 10/09/2018 - 11:09 By Dylan Kosaski When I left for MRM2017 in Region 4 on a Friday morning with 19 other student pharmacists from the Ferris State University College of Pharmacy, I could never have predicted the whirlwind ...Only allowed members have full access to this content.Log in to view full content. (Click for more...) Glutamine may be an option for postinfectious irritable bowel syndrome 10/9/2018 10:20:57 AM Key Point:Use of glutamine supplementation in patients with postinfectious diarrhea-predominant irritable bowel syndrome (IBS-D) resulted in greater improvements in gastrointestinal (GI) symptoms and changes in daily bowel movement frequency, stool form, and intestinal permeability compared with placebo, according to results of a small study published in Gut. (Click for more...) Patients labeled as penicillin-allergic and MRSA and C. difficile infections 10/9/2018 10:12:32 AM Key Point:The risk of methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections was higher in patients who reported a penicillin allergy compared with those who did not, according to results of an observational study published in BMJ. The risks of developing MRSA and C. difficile were reportedly mediated by use of alternative broad-spectrum non–beta-lactam antibiotics. (Click for more...) 5% Dextrose Injection (PVC-free and DEHP-free) 10/8/2018 8:00:00 PM Drug: 5% Dextrose Injection (PVC-free and DEHP-free), Revision Date: Tue, 09 Oct 2018 (Click for more...) Alpha-1 Proteinase Inhibitor 10/8/2018 8:00:00 PM Drug: Alpha-1 Proteinase Inhibitor, Revision Date: Tue, 09 Oct 2018 (Click for more...) Calcitriol Injection 10/8/2018 8:00:00 PM Drug: Calcitriol Injection, Revision Date: Tue, 09 Oct 2018 (Click for more...) Dorzolamide Ophthalmic Solution 10/8/2018 8:00:00 PM Drug: Dorzolamide Ophthalmic Solution, Revision Date: Tue, 09 Oct 2018 (Click for more...) Gentamicin Sulfate Ophthalmic Ointment 10/8/2018 8:00:00 PM Drug: Gentamicin Sulfate Ophthalmic Ointment, Revision Date: Tue, 09 Oct 2018 (Click for more...) Hydroxyethyl Starch in Sodium Chloride Injection 10/8/2018 8:00:00 PM Drug: Hydroxyethyl Starch in Sodium Chloride Injection, Revision Date: Tue, 09 Oct 2018 (Click for more...) Midodrine Tablets 10/8/2018 8:00:00 PM Drug: Midodrine Tablets, Revision Date: Tue, 09 Oct 2018 (Click for more...) Multiple Vitamins for Infusion 10/8/2018 8:00:00 PM Drug: Multiple Vitamins for Infusion, Revision Date: Tue, 09 Oct 2018 (Click for more...) Sterile Talc 10/8/2018 8:00:00 PM Drug: Sterile Talc, Revision Date: Tue, 09 Oct 2018 (Click for more...) Sterile Water for Injection Large Volume Bags 10/8/2018 8:00:00 PM Drug: Sterile Water for Injection Large Volume Bags, Revision Date: Tue, 09 Oct 2018 (Click for more...) Sufentanil Injection 10/8/2018 8:00:00 PM Drug: Sufentanil Injection, Revision Date: Tue, 09 Oct 2018 (Click for more...) Mitomycin Kit for Ophthalmic Use 10/8/2018 8:00:00 PM Drug: Mitomycin Kit for Ophthalmic Use, Revision Date: Tue, 09 Oct 2018 (Click for more...) WVU community invited to State of the University address today (10/8) 10/8/2018 12:00:00 AM WVU President Gordon Gee will deliver a State of the University address today (Oct. 8) at 3:15 p.m. at the Ruby Grand Hall, Erickson Alumni Center. Faculty, staff and students are encouraged to use the PRT, buses or carpool to the event. (Click for more...) Amino Acid Products 10/7/2018 8:00:00 PM Drug: Amino Acid Products, Revision Date: Mon, 08 Oct 2018 (Click for more...) Dexamethasone Sodium Phosphate Injection 10/7/2018 8:00:00 PM Drug: Dexamethasone Sodium Phosphate Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) Diphenhydramine Injection 10/7/2018 8:00:00 PM Drug: Diphenhydramine Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) Famotidine Injection 10/7/2018 8:00:00 PM Drug: Famotidine Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) Metoclopramide Injection 10/7/2018 8:00:00 PM Drug: Metoclopramide Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) Norepinephrine Bitartrate Injection 10/7/2018 8:00:00 PM Drug: Norepinephrine Bitartrate Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) Ondansetron Hydrochloride Injection 10/7/2018 8:00:00 PM Drug: Ondansetron Hydrochloride Injection, Revision Date: Mon, 08 Oct 2018 (Click for more...) Sodium Fluoride Chewable Tablets 10/7/2018 8:00:00 PM Drug: Sodium Fluoride Chewable Tablets, Revision Date: Mon, 08 Oct 2018 (Click for more...) SoP students collect empty Coca-Cola products to help WVU Medicine Children's 10/5/2018 12:00:00 AM The Industry Pharmacist Organization (IPhO) chapter at WVU started with one can and built a mountain. They've been collecting the empty Coca-Cola cans and bottles to raise money for WVU Medicine Children's. For each can or bottle donated, Coca-Cola is donating $5! The drive will continue until 3 p.m. today. Thanks to everyone at the Health Sciences Center for participating. #Let'sGo! (Click for more...) 2% Lidocaine Hydrochloride Topical Jelly 10/4/2018 8:00:00 PM Drug: 2% Lidocaine Hydrochloride Topical Jelly, Revision Date: Fri, 05 Oct 2018 (Click for more...) Belladonna and Opium Suppositories 10/4/2018 8:00:00 PM Drug: Belladonna and Opium Suppositories, Revision Date: Fri, 05 Oct 2018 (Click for more...) Carbidopa and Levodopa Extended-Release Tablets 10/4/2018 8:00:00 PM Drug: Carbidopa and Levodopa Extended-Release Tablets, Revision Date: Fri, 05 Oct 2018 (Click for more...) Cefepime Injection 10/4/2018 8:00:00 PM Drug: Cefepime Injection, Revision Date: Fri, 05 Oct 2018 (Click for more...) Cefoxitin Sodium Injection 10/4/2018 8:00:00 PM Drug: Cefoxitin Sodium Injection, Revision Date: Fri, 05 Oct 2018 (Click for more...) Methadone Injection 10/4/2018 8:00:00 PM Drug: Methadone Injection, Revision Date: Fri, 05 Oct 2018 (Click for more...) 0.9% Sodium Chloride Large Volume Bags 10/3/2018 8:00:00 PM Drug: 0.9% Sodium Chloride Large Volume Bags, Revision Date: Thu, 04 Oct 2018 (Click for more...) 0.9% Sodium Chloride Small Volume Bags (< 150 mL) 10/3/2018 8:00:00 PM Drug: 0.9% Sodium Chloride Small Volume Bags (< 150 mL), Revision Date: Thu, 04 Oct 2018 (Click for more...) 5% Dextrose Injection 10/3/2018 8:00:00 PM Drug: 5% Dextrose Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Amiodarone Injection 10/3/2018 8:00:00 PM Drug: Amiodarone Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Azithromycin Injection 10/3/2018 8:00:00 PM Drug: Azithromycin Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Ceftriaxone Sodium Injection 10/3/2018 8:00:00 PM Drug: Ceftriaxone Sodium Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Cefuroxime Sodium Injection 10/3/2018 8:00:00 PM Drug: Cefuroxime Sodium Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Ciprofloxacin Injection 10/3/2018 8:00:00 PM Drug: Ciprofloxacin Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Clindamycin Phosphate Injection 10/3/2018 8:00:00 PM Drug: Clindamycin Phosphate Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Lactated Ringer's Injection 10/3/2018 8:00:00 PM Drug: Lactated Ringer's Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Lorazepam Tablets 10/3/2018 8:00:00 PM Drug: Lorazepam Tablets, Revision Date: Thu, 04 Oct 2018 (Click for more...) Methocarbamol Tablets 10/3/2018 8:00:00 PM Drug: Methocarbamol Tablets, Revision Date: Thu, 04 Oct 2018 (Click for more...) Methylene Blue 10/3/2018 8:00:00 PM Drug: Methylene Blue, Revision Date: Thu, 04 Oct 2018 (Click for more...) Metronidazole Hydrochloride Injection 10/3/2018 8:00:00 PM Drug: Metronidazole Hydrochloride Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Mineral Oil and Petrolatum Ophthalmic Ointment 10/3/2018 8:00:00 PM Drug: Mineral Oil and Petrolatum Ophthalmic Ointment, Revision Date: Thu, 04 Oct 2018 (Click for more...) Pentostatin Injection 10/3/2018 8:00:00 PM Drug: Pentostatin Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Potassium Chloride Injection 10/3/2018 8:00:00 PM Drug: Potassium Chloride Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Rosuvastatin Calcium Tablets 10/3/2018 8:00:00 PM Drug: Rosuvastatin Calcium Tablets, Revision Date: Thu, 04 Oct 2018 (Click for more...) Sincalide Injection 10/3/2018 8:00:00 PM Drug: Sincalide Injection, Revision Date: Thu, 04 Oct 2018 (Click for more...) Spironolactone Tablets 10/3/2018 8:00:00 PM Drug: Spironolactone Tablets, Revision Date: Thu, 04 Oct 2018 (Click for more...) Prothrombin Complex Concentrate (Kcentra) 10/3/2018 8:00:00 PM Drug: Prothrombin Complex Concentrate (Kcentra), Revision Date: Thu, 04 Oct 2018 (Click for more...) Ampicillin Sodium and Sulbactam Sodium Injection 10/2/2018 8:00:00 PM Drug: Ampicillin Sodium and Sulbactam Sodium Injection, Revision Date: Wed, 03 Oct 2018 (Click for more...) Fluphenazine Tablets 10/2/2018 8:00:00 PM Drug: Fluphenazine Tablets, Revision Date: Wed, 03 Oct 2018 (Click for more...) Furosemide Tablets 10/2/2018 8:00:00 PM Drug: Furosemide Tablets, Revision Date: Wed, 03 Oct 2018 (Click for more...) Lorazepam Injection 10/2/2018 8:00:00 PM Drug: Lorazepam Injection, Revision Date: Wed, 03 Oct 2018 (Click for more...) Mafenide Acetate Powder for Solution 10/2/2018 8:00:00 PM Drug: Mafenide Acetate Powder for Solution, Revision Date: Wed, 03 Oct 2018 (Click for more...) Methotrexate Injection 10/2/2018 8:00:00 PM Drug: Methotrexate Injection, Revision Date: Wed, 03 Oct 2018 (Click for more...) WVU APhA-ASP celebrates American Pharmacists Month 10/2/2018 12:00:00 AM October is American Pharmacists Month. WVU APhA-ASP and other student organizations will sponsor an entire month full of events to help celebrate the profession. Check out the list below and mark your calendar. (Click for more...) Pharmaceutical and Pharmacological Sciences Seminar Series 10/2/2018 12:00:00 AM Please join the West Virginia University School of Pharmacy on Oct. 9 at 1:00 p.m. in Room 3084 HSC-N for the Pharmaceutical and Pharmacological Sciences Seminar Series. John D. Imig, Ph.D., will present, "Eicosanoid Drugs: Prospects for Treating Human Diseases." Imig is a professor of pharmacology and toxicology as well as director of the Drug Discovery Center at the Medical College of Wisconsin. (Click for more...) Doing our part to improve drug safety 10/1/2018 11:59:37 PM Pharmacovigilance and drug safety teams are never short of work. There’s a vast amount of peer-reviewed literature to sift through for adverse event information. Over 800,000 pharmacology and biomedicine articles are published annually, but only ~5% of those contain information relevant to pharmacovigilance activities. Then there is the complexity of the workflow itself, with different […] (Click for more...) Cefpodoxime Oral Suspension 10/1/2018 8:00:00 PM Drug: Cefpodoxime Oral Suspension, Revision Date: Tue, 02 Oct 2018 (Click for more...) Diclofenac 0.1% Ophthalmic Solution 10/1/2018 8:00:00 PM Drug: Diclofenac 0.1% Ophthalmic Solution, Revision Date: Tue, 02 Oct 2018 (Click for more...) Meropenem Injection 10/1/2018 8:00:00 PM Drug: Meropenem Injection, Revision Date: Tue, 02 Oct 2018 (Click for more...) Nelarabine Injection 10/1/2018 8:00:00 PM Drug: Nelarabine Injection, Revision Date: Tue, 02 Oct 2018 (Click for more...) Penicillin G Procaine Injection 10/1/2018 8:00:00 PM Drug: Penicillin G Procaine Injection, Revision Date: Tue, 02 Oct 2018 (Click for more...) Ranitidine Injection 10/1/2018 8:00:00 PM Drug: Ranitidine Injection, Revision Date: Tue, 02 Oct 2018 (Click for more...) Thrombin Topical Solution (Bovine) 10/1/2018 8:00:00 PM Drug: Thrombin Topical Solution (Bovine), Revision Date: Tue, 02 Oct 2018 (Click for more...) Fomepizole Injection 10/1/2018 8:00:00 PM Drug: Fomepizole Injection, Revision Date: Tue, 02 Oct 2018 (Click for more...) Three-drug, low-dose, fixed-combination product is effective for BP control 10/1/2018 2:36:17 PM Key Point:A three-drug, low-dose, fixed-combination dosage form resulted in better blood pressure (BP) control at 6 months compared with usual care in patients with mild to moderate hypertension, according to results of a randomized trial published in JAMA. (Click for more...) Some older adults with type 2 diabetes may be overtreated 10/1/2018 2:06:09 PM Key Point:Approximately one-quarter of older adults (≥75 y) with type 2 diabetes were treated with medications associated with a high risk of hypoglycemia to achieve tight glycemic control, according to an observational analysis of a large U.S. outpatient cohort published in the Journal of the American Geriatrics Society. (Click for more...) 0.9% Sodium Chloride 10 mL, 20 mL, and 50 mL Preservative Free Vials and Syringes 9/30/2018 8:00:00 PM Drug: 0.9% Sodium Chloride 10 mL, 20 mL, and 50 mL Preservative Free Vials and Syringes, Revision Date: Mon, 01 Oct 2018 (Click for more...) Fluorouracil Injection 9/30/2018 8:00:00 PM Drug: Fluorouracil Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) Granisetron Hydrochloride Injection 9/30/2018 8:00:00 PM Drug: Granisetron Hydrochloride Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) Metoprolol Injection 9/30/2018 8:00:00 PM Drug: Metoprolol Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) Nitrofurantoin Oral Suspension 9/30/2018 8:00:00 PM Drug: Nitrofurantoin Oral Suspension, Revision Date: Mon, 01 Oct 2018 (Click for more...) 3% and 5% Sodium Chloride Large Volume Injection 9/30/2018 8:00:00 PM Drug: 3% and 5% Sodium Chloride Large Volume Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) Dipyridamole Injection 9/30/2018 8:00:00 PM Drug: Dipyridamole Injection, Revision Date: Mon, 01 Oct 2018 (Click for more...) Rare Disease Drug Repurposing Datathon Launching 9/28/2018 12:53:15 PM Would you and your organization like to use your skills and expertise to help defeat rare diseases? On October 9, the Rare Disease Drug Repurposing Datathon is launching, offering data scientists a special opportunity to work together to uncover insights on rare conditions like chronic pancreatitis, Meniere’s disease, retinitis pigmentosa and obsessive-compulsive disorder (OCD). In […] (Click for more...) 50% Dextrose Injection 9/27/2018 8:00:00 PM Drug: 50% Dextrose Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Aminocaproic Acid Injection 9/27/2018 8:00:00 PM Drug: Aminocaproic Acid Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Dalbavancin Injection 9/27/2018 8:00:00 PM Drug: Dalbavancin Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Deferoxamine Injection 9/27/2018 8:00:00 PM Drug: Deferoxamine Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Dexmedetomidine Hydrochloride Injection 9/27/2018 8:00:00 PM Drug: Dexmedetomidine Hydrochloride Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Dopamine Hydrochloride Injection 9/27/2018 8:00:00 PM Drug: Dopamine Hydrochloride Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Epinephrine Injection 9/27/2018 8:00:00 PM Drug: Epinephrine Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Methylphenidate Extended-Release Oral Suspension and Chewable Tablets 9/27/2018 8:00:00 PM Drug: Methylphenidate Extended-Release Oral Suspension and Chewable Tablets, Revision Date: Fri, 28 Sep 2018 (Click for more...) Potassium Acetate Injection 9/27/2018 8:00:00 PM Drug: Potassium Acetate Injection, Revision Date: Fri, 28 Sep 2018 (Click for more...) Valsartan Tablets 9/27/2018 8:00:00 PM Drug: Valsartan Tablets, Revision Date: Fri, 28 Sep 2018 (Click for more...) First-year pharmacy students discuss the importance of cultural awareness in healthcare 9/27/2018 12:00:00 AM Fasting is a common practice in many religions, but what if a patient's religious beliefs keep him or her from taking a life-saving medication? How do pharmacists work around language barriers? To create cultural awareness among first-year students (P-1) and help them to navigate related challenges in a professional, caring way, the WVU School of Pharmacy has incorporated a new activity into the P-1 curriculum that addresses culture and diversity. (Click for more...) Pharmacy alumnus among homecoming awardees to be honored for extraordinary service to WVU 9/27/2018 12:00:00 AM In just 10 years, School of Pharmacy alumnus Dr. Brian Lawson (PharmD, 2008) has already provided what some would consider a lifetime of service to his alma mater. On Oct. 6, Mountaineer Nation will applaud his dedication as he accepts a prestigious award from the WVU Alumni Association during halftime of the WVU/Kansas Homecoming game. (Click for more...) Cyclosporine Capsules 9/26/2018 8:00:00 PM Drug: Cyclosporine Capsules, Revision Date: Thu, 27 Sep 2018 (Click for more...) Penicillamine 9/26/2018 8:00:00 PM Drug: Penicillamine, Revision Date: Thu, 27 Sep 2018 (Click for more...) WVU alumnus earns national award for service to the pharmacy profession 9/26/2018 12:00:00 AM The National Association of Chain Drug Stores is recognizing School of Pharmacy alumnus Mike Podgurski (BS Pharmacy, 1972) with its highest honor. Podgurski is the 2018 recipient of the Harold W. Pratt Award which recognizes individuals whose activities have contributed to the promotion, recognition and improvement of the practice of pharmacy in the chain pharmacy setting. (Click for more...) 14.6% Sodium Chloride Concentrated Solution for Injection 9/25/2018 8:00:00 PM Drug: 14.6% Sodium Chloride Concentrated Solution for Injection, Revision Date: Wed, 26 Sep 2018 (Click for more...) Mitoxantrone Hydrochloride Injection 9/25/2018 8:00:00 PM Drug: Mitoxantrone Hydrochloride Injection, Revision Date: Wed, 26 Sep 2018 (Click for more...) Lorazepam Oral Solution 9/25/2018 8:00:00 PM Drug: Lorazepam Oral Solution, Revision Date: Wed, 26 Sep 2018 (Click for more...) Statins decrease osteoporosis and fracture risk after stroke 9/25/2018 12:18:39 PM Key Point:Patients who used statins after a stroke had a reduced risk of osteoporosis, hip fracture, and vertebral fracture compared with those who did not use statins, with a dose-effect relationship observed, according to results of an observational study published in the Journal of Clinical Endocrinology and Metabolism. (Click for more...) Unsafe use of zolpidem is common 9/25/2018 11:26:28 AM Key Point:An assessment of national survey data from 2015 showed that many patients used zolpidem in unsafe ways, such as by administering higher-than-recommended doses (females and older adults), using the drug for a sustained period, and combining it with other central nervous system (CNS) depressants. (Click for more...) Isocarboxazid Tablets 9/24/2018 8:00:00 PM Drug: Isocarboxazid Tablets, Revision Date: Tue, 25 Sep 2018 (Click for more...) Moxifloxacin Injection 9/24/2018 8:00:00 PM Drug: Moxifloxacin Injection, Revision Date: Tue, 25 Sep 2018 (Click for more...) Free health screenings and prize opportunities at the Mountainlair 9/24/2018 12:00:00 AM Flu shots, Hemoglobin A1C tests, free health care screenings and prize opportunities will be available at the WVU Healthy Living Fair at the Mountainlair on Thursday, Sept. 27 from 10 a.m.– 2 p.m. (Click for more...) Health Sciences to host "Pandemics and Vaccinations" Expert Panel on Oct. 9 9/24/2018 12:00:00 AM Reality or fiction – just how likely is a pandemic illness? Join leading health experts as they discuss the reality of a pandemic illness on Tuesday, Oct. 9, at 4 p.m. at the Health Sciences Center's Okey Patteson Auditorium. (Click for more...) Bacteriostatic 0.9% Sodium Chloride Vials 9/23/2018 8:00:00 PM Drug: Bacteriostatic 0.9% Sodium Chloride Vials, Revision Date: Mon, 24 Sep 2018 (Click for more...) Fluconazole Injection 9/19/2018 8:00:00 PM Drug: Fluconazole Injection, Revision Date: Thu, 20 Sep 2018 (Click for more...) Sodium Polystyrene Sulfonate Oral or Rectal Suspension 9/19/2018 8:00:00 PM Drug: Sodium Polystyrene Sulfonate Oral or Rectal Suspension, Revision Date: Thu, 20 Sep 2018 (Click for more...) Alcohol Dehydrated Injection (Ethanol) 9/18/2018 8:00:00 PM Drug: Alcohol Dehydrated Injection (Ethanol), Revision Date: Wed, 19 Sep 2018 (Click for more...) Complementary medicines associated with poor outcomes in patients with cancer 9/18/2018 11:58:14 AM Key Point:Patients with cancer who used complementary medicines had higher refusal rates of surgery, chemotherapy, radiotherapy, and hormone therapy compared with those who did not use these alternative therapies, resulting in greater risk of death, according to results of a retrospective observational study published in JAMA Oncology. (Click for more...) Vitamin D levels associated with better pregnancy outcomes 9/18/2018 10:23:41 AM Key Point:In women with a history of pregnancy losses and no diagnosis of infertility, those with sufficient preconception vitamin D serum levels had increased pregnancy rates and live births compared with women who had insufficient levels, according to a report published in The Lancet Diabetes and Endocrinology. (Click for more...) Amino Acid Products with Electrolytes and Calcium 9/17/2018 8:00:00 PM Drug: Amino Acid Products with Electrolytes and Calcium, Revision Date: Tue, 18 Sep 2018 (Click for more...) Amino Acids in Dextrose 9/17/2018 8:00:00 PM Drug: Amino Acids in Dextrose, Revision Date: Tue, 18 Sep 2018 (Click for more...) Buspirone Tablets 9/17/2018 8:00:00 PM Drug: Buspirone Tablets, Revision Date: Tue, 18 Sep 2018 (Click for more...) Melphalan Tablets 9/17/2018 8:00:00 PM Drug: Melphalan Tablets, Revision Date: Tue, 18 Sep 2018 (Click for more...) Polyvinyl Alcohol (Artificial Tears) Ophthalmic Solution 9/17/2018 8:00:00 PM Drug: Polyvinyl Alcohol (Artificial Tears) Ophthalmic Solution, Revision Date: Tue, 18 Sep 2018 (Click for more...) Albuterol Inhalation Solution 9/16/2018 8:00:00 PM Drug: Albuterol Inhalation Solution, Revision Date: Mon, 17 Sep 2018 (Click for more...) Indocyanine Green 9/16/2018 8:00:00 PM Drug: Indocyanine Green, Revision Date: Mon, 17 Sep 2018 (Click for more...) Nalbuphine Injection 9/15/2018 8:00:00 PM Drug: Nalbuphine Injection, Revision Date: Sun, 16 Sep 2018 (Click for more...) It's a "Code Blue" at the WVU Health Sciences Center as students train for cardiac arrest patients 9/14/2018 12:00:00 AM Witness WVU Health Sciences students and local emergency services professionals perform a "Code Blue" emergency response to a simulated cardiac arrest situation as part of National Healthcare Simulation Week. (Click for more...) Octreotide Injection 9/12/2018 8:00:00 PM Drug: Octreotide Injection, Revision Date: Thu, 13 Sep 2018 (Click for more...) Kappa Psi members receive international recognition for their academic achievments 9/12/2018 12:00:00 AM The largest professional pharmacy fraternity in the world is celebrating a group of students at the West Virginia University School of Pharmacy for their outstanding academic achievements. (Click for more...) Atenolol and Chlorthalidone Tablets 9/11/2018 8:00:00 PM Drug: Atenolol and Chlorthalidone Tablets, Revision Date: Wed, 12 Sep 2018 (Click for more...) Estradiol Valerate Injection 9/11/2018 8:00:00 PM Drug: Estradiol Valerate Injection, Revision Date: Wed, 12 Sep 2018 (Click for more...) Hepatitis A Virus Vaccine Inactivated 9/11/2018 8:00:00 PM Drug: Hepatitis A Virus Vaccine Inactivated, Revision Date: Wed, 12 Sep 2018 (Click for more...) Hepatitis B Vaccine (Recombinant) 9/11/2018 8:00:00 PM Drug: Hepatitis B Vaccine (Recombinant), Revision Date: Wed, 12 Sep 2018 (Click for more...) Hydroxocobalamin Injection 9/10/2018 8:00:00 PM Drug: Hydroxocobalamin Injection, Revision Date: Tue, 11 Sep 2018 (Click for more...) Atenolol tablets 9/10/2018 8:00:00 PM Drug: Atenolol tablets, Revision Date: Tue, 11 Sep 2018 (Click for more...) WVU pharmacy professor to present at country's largest pain management conference 9/7/2018 12:00:00 AM Healthcare professionals attending the largest pain management conference in the United States may learn a thing or two about treating pain the "West Virginia Way." (Click for more...) Hypromellose Ophthalmic Solution 9/6/2018 8:00:00 PM Drug: Hypromellose Ophthalmic Solution, Revision Date: Fri, 07 Sep 2018 (Click for more...) WVU School of Pharmacy announces plans for Homecoming 2018 9/6/2018 12:00:00 AM The WVU School of Pharmacy will welcome alumni back to Morgantown the first weekend in October for Homecoming festivities. (Click for more...) Lidocaine Hydrochloride and 5% Dextrose Injection 9/5/2018 8:00:00 PM Drug: Lidocaine Hydrochloride and 5% Dextrose Injection, Revision Date: Thu, 06 Sep 2018 (Click for more...) Heparin Injection 9/4/2018 8:00:00 PM Drug: Heparin Injection, Revision Date: Wed, 05 Sep 2018 (Click for more...) Leuprolide Acetate 14-Day Kit 9/4/2018 8:00:00 PM Drug: Leuprolide Acetate 14-Day Kit, Revision Date: Wed, 05 Sep 2018 (Click for more...) Levetiracetam Injection 9/4/2018 8:00:00 PM Drug: Levetiracetam Injection, Revision Date: Wed, 05 Sep 2018 (Click for more...) Multiple Electrolytes Large Volume Solutions for Injection 9/3/2018 8:00:00 PM Drug: Multiple Electrolytes Large Volume Solutions for Injection, Revision Date: Tue, 04 Sep 2018 (Click for more...) Sodium Acetate Injection 9/3/2018 8:00:00 PM Drug: Sodium Acetate Injection, Revision Date: Tue, 04 Sep 2018 (Click for more...) Rocuronium Injection 8/30/2018 8:00:00 PM Drug: Rocuronium Injection, Revision Date: Fri, 31 Aug 2018 (Click for more...) Scopolamine Transdermal System 8/30/2018 8:00:00 PM Drug: Scopolamine Transdermal System, Revision Date: Fri, 31 Aug 2018 (Click for more...) Gillison to present Annual DeLynn Lecture 8/30/2018 12:00:00 AM The WVU Cancer Institute will hold its Annual DeLynn Lecture with Maura L. Gillison, MD, PhD, who will lecture on HPV and the Host Genome, at 4 pm on Tuesday, Sept. 4, in the WVU Health Sciences Center's Fukushima Auditorium (room 1901). A Q&A session will follow the lecture. The event is free and open to the public. For those who cannot attend, the event also will be webcast. (Click for more...) SoP alumni and faculty win awards at WVPA Convention 8/29/2018 12:00:00 AM Four West Virginia University School of Pharmacy alumni and two faculty members received awards at the 111th annual West Virginia Pharmacy Association (WVPA) Convention. (Click for more...) Ciprofloxacin Ophthalmic Solution 8/28/2018 8:00:00 PM Drug: Ciprofloxacin Ophthalmic Solution, Revision Date: Wed, 29 Aug 2018 (Click for more...) Desiccated Thyroid Tablets 8/28/2018 8:00:00 PM Drug: Desiccated Thyroid Tablets, Revision Date: Wed, 29 Aug 2018 (Click for more...) Oxacillin Sodium Injection 8/28/2018 8:00:00 PM Drug: Oxacillin Sodium Injection, Revision Date: Wed, 29 Aug 2018 (Click for more...) Methyldopa Tablets 8/27/2018 8:00:00 PM Drug: Methyldopa Tablets, Revision Date: Tue, 28 Aug 2018 (Click for more...) Vincristine Sulfate Injection 8/27/2018 8:00:00 PM Drug: Vincristine Sulfate Injection, Revision Date: Tue, 28 Aug 2018 (Click for more...) WVU Pharmacy students receive white coats 8/27/2018 12:00:00 AM Members of the West Virginia UniversitySchool of Pharmacy Class of 2022 recently received the most significant symbol of their graduate career — the white coat. (Click for more...) Atropine Ophthalmic Solution 8/26/2018 8:00:00 PM Drug: Atropine Ophthalmic Solution, Revision Date: Mon, 27 Aug 2018 (Click for more...) Morphine PCA Vials 8/23/2018 8:00:00 PM Drug: Morphine PCA Vials, Revision Date: Fri, 24 Aug 2018 (Click for more...) WVU in the news: WVU researchers working to stop cancer-growth protein 8/23/2018 12:00:00 AM Yehenew Agazie, an associate professor of biochemistry at the WVU School of Medicine, received a $1.6 million grant from the National Institutes of Health to investigate a new breast cancer treatment that is especially effective against recurrent tumors. (Click for more...) Postdoc Appreciation Event 8/23/2018 12:00:00 AM On September 18th, the Office of Research and Graduate Education will host the annual Postdoc Appreciation Celebration during the National Postdoc Appreciation week. (Click for more...) Etomidate Injection 8/21/2018 8:00:00 PM Drug: Etomidate Injection, Revision Date: Wed, 22 Aug 2018 (Click for more...) WVU Pharmacy students are winning! 8/21/2018 12:00:00 AM On August 18, four third-year students showed off their self-care knowledge at the annual West Virginia Pharmacists Association meeting in Charleston. The team comprised of Lindsay Mason, Mai Do, Lucy Luo and Shaina Kopelov won the Student Pharmacist Self Care Championship. They competed against a team from Marshall University School of Pharmacy in a jeopardy style game. The students were challenged to identify and explain aspects of the effective and safe practice of pharmacy self-care treatments. In additiion, they were asked to identify at least two over-the-counter prescription medication interactions that pharmacists should be aware of, and list three OTC medications and their use. (Click for more...) Abciximab Injection 8/19/2018 8:00:00 PM Drug: Abciximab Injection, Revision Date: Mon, 20 Aug 2018 (Click for more...) Belatacept Injection 8/19/2018 8:00:00 PM Drug: Belatacept Injection, Revision Date: Mon, 20 Aug 2018 (Click for more...) Doxorubicin Injection 8/19/2018 8:00:00 PM Drug: Doxorubicin Injection, Revision Date: Mon, 20 Aug 2018 (Click for more...) Mupirocin Calcium 2% Cream 8/19/2018 8:00:00 PM Drug: Mupirocin Calcium 2% Cream, Revision Date: Mon, 20 Aug 2018 (Click for more...) Nitroglycerin Injection 8/11/2018 8:00:00 PM Drug: Nitroglycerin Injection, Revision Date: Sun, 12 Aug 2018 (Click for more...) 5% Lidocaine and 7.5% Dextrose Injection 8/7/2018 8:00:00 PM Drug: 5% Lidocaine and 7.5% Dextrose Injection, Revision Date: Wed, 08 Aug 2018 (Click for more...) Ciprofloxacin Oral Suspension 8/7/2018 8:00:00 PM Drug: Ciprofloxacin Oral Suspension, Revision Date: Wed, 08 Aug 2018 (Click for more...) Eflornithine Hydrochloride Cream 8/7/2018 8:00:00 PM Drug: Eflornithine Hydrochloride Cream, Revision Date: Wed, 08 Aug 2018 (Click for more...) Reteplase Injection 8/7/2018 8:00:00 PM Drug: Reteplase Injection, Revision Date: Wed, 08 Aug 2018 (Click for more...) Theophylline Extended-Release Tablets 8/7/2018 8:00:00 PM Drug: Theophylline Extended-Release Tablets, Revision Date: Wed, 08 Aug 2018 (Click for more...) Multiple Vitamin Oral Liquid 8/7/2018 8:00:00 PM Drug: Multiple Vitamin Oral Liquid, Revision Date: Wed, 08 Aug 2018 (Click for more...) Erythromycin Lactobionate Injection 8/5/2018 8:00:00 PM Drug: Erythromycin Lactobionate Injection, Revision Date: Mon, 06 Aug 2018 (Click for more...) Selenium Injection (as Selenious Acid) 8/5/2018 8:00:00 PM Drug: Selenium Injection (as Selenious Acid), Revision Date: Mon, 06 Aug 2018 (Click for more...) Yellow Fever Vaccine 7/31/2018 8:00:00 PM Drug: Yellow Fever Vaccine, Revision Date: Wed, 01 Aug 2018 (Click for more...) Amoxicillin and Clavulanate 1000 mg/62.5 mg Extended-Release Tablets 7/31/2018 8:00:00 PM Drug: Amoxicillin and Clavulanate 1000 mg/62.5 mg Extended-Release Tablets, Revision Date: Wed, 01 Aug 2018 (Click for more...) Flurbiprofen Sodium Ophthalmic Solution 7/30/2018 8:00:00 PM Drug: Flurbiprofen Sodium Ophthalmic Solution, Revision Date: Tue, 31 Jul 2018 (Click for more...) Mupirocin Calcium 2% Nasal Ointment 7/24/2018 8:00:00 PM Drug: Mupirocin Calcium 2% Nasal Ointment, Revision Date: Wed, 25 Jul 2018 (Click for more...) Doctors target opioid epidemic by learning new approaches to pain treatment 7/19/2018 12:00:00 AM MORGANTOWN, W.Va. – Twice a month, healthcare providers from rural health centers all across West Virginia meet in a virtual classroom to discuss how best to help their patients cope with chronic pain. (Click for more...) Ethiodized Oil 7/16/2018 8:00:00 PM Drug: Ethiodized Oil, Revision Date: Tue, 17 Jul 2018 (Click for more...) Liotrix (Levothyroxine/Liothyronine T4/T3) 7/8/2018 8:00:00 PM Drug: Liotrix (Levothyroxine/Liothyronine T4/T3), Revision Date: Mon, 09 Jul 2018 (Click for more...) Ipratropium Bromide Metered-Dose Inhaler 7/8/2018 8:00:00 PM Drug: Ipratropium Bromide Metered-Dose Inhaler, Revision Date: Mon, 09 Jul 2018 (Click for more...) Thiamine Injection 7/5/2018 8:00:00 PM Drug: Thiamine Injection, Revision Date: Fri, 06 Jul 2018 (Click for more...) Caffeine and Sodium Benzoate Injection 7/4/2018 8:00:00 PM Drug: Caffeine and Sodium Benzoate Injection, Revision Date: Thu, 05 Jul 2018 (Click for more...) Trace Elements Injection 7/4/2018 8:00:00 PM Drug: Trace Elements Injection, Revision Date: Thu, 05 Jul 2018 (Click for more...) Vitamin K (Phytonadione) Injection 7/4/2018 8:00:00 PM Drug: Vitamin K (Phytonadione) Injection, Revision Date: Thu, 05 Jul 2018 (Click for more...) Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 6/26/2018 8:00:00 PM Drug: Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, Revision Date: Wed, 27 Jun 2018 (Click for more...) Three West Virginia pharmacists named WVU School of Pharmacy's Preceptor of the Year 6/26/2018 12:00:00 AM Bill Renner, Terry Davis and Matt Pletcher received the 2018 WVU School of Pharmacy Preceptor of the Year award on Friday, June 8 at the School's annual Alumni Reunion Dinner. (Click for more...) School of Pharmacy DAP student wins national history award 6/25/2018 12:00:00 AM School of Pharmacy Direct Admit Pathway (DAP) student Brennan Lawless is off to a fast start as a West Virginia University freshman. The Daniels, West Virginia, native recently won a National History Day award. (Click for more...) Dalbavancin Injection 6/20/2018 8:00:00 PM Drug: Dalbavancin Injection, Revision Date: Thu, 21 Jun 2018 (Click for more...) Asparaginase Erwinia chrysanthemi 6/19/2018 8:00:00 PM Drug: Asparaginase Erwinia chrysanthemi, Revision Date: Wed, 20 Jun 2018 (Click for more...) Haloperidol Lactate Injection 6/19/2018 8:00:00 PM Drug: Haloperidol Lactate Injection, Revision Date: Wed, 20 Jun 2018 (Click for more...) New rural scholars program available to health professions students in West Virginia 6/14/2018 12:00:00 AM West Virginia AHEC Rural Community Health Scholars is a new, highly selective program available to 75 of West Virginia's top health professions students interested in practicing in rural or underserved communities; WVU and non-WVU students alike may participate. (Click for more...) WVU researchers identify four factors that predict chronic opioid use 5/29/2018 12:00:00 AM Four factors increase the odds that a patient will wind up on chronic opioid therapy, suggests research conducted by a team of researchers led by Nilanjana Dwibedi, assistant professor in the West Virginia University School of Pharmacy. (Click for more...) Amoxapine Tablets 5/28/2018 8:00:00 PM Drug: Amoxapine Tablets, Revision Date: Tue, 29 May 2018 (Click for more...) Oseltamivir Oral Suspension 5/28/2018 8:00:00 PM Drug: Oseltamivir Oral Suspension, Revision Date: Tue, 29 May 2018 (Click for more...) Penicillin G Benzathine / Penicillin G Procaine 5/24/2018 8:00:00 PM Drug: Penicillin G Benzathine / Penicillin G Procaine, Revision Date: Fri, 25 May 2018 (Click for more...) Pantoprazole Injection 5/22/2018 8:00:00 PM Drug: Pantoprazole Injection, Revision Date: Wed, 23 May 2018 (Click for more...) Doxycycline Hyclate Injection 5/20/2018 8:00:00 PM Drug: Doxycycline Hyclate Injection, Revision Date: Mon, 21 May 2018 (Click for more...) Thiotepa for Injection 5/13/2018 8:00:00 PM Drug: Thiotepa for Injection, Revision Date: Mon, 14 May 2018 (Click for more...) School of Pharmacy announces changes to its leadership team 5/10/2018 12:00:00 AM The West Virginia University School of Pharmacy is pleased to announce changes to its leadership team. Dr. Paul Lockman has been appointed the position of senior associate dean for research and strategic initiatives in addition to Mylan Endowed Chair of Pharmacology, while Dr. Mary Stamatakis has been appointed to senior associate dean of academic affairs and educational innovation. (Click for more...) 25% Dextrose Injection 5/9/2018 8:00:00 PM Drug: 25% Dextrose Injection, Revision Date: Thu, 10 May 2018 (Click for more...) Scopolamine Transdermal System 5/7/2018 8:00:00 PM